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editorial
“If it seems to neurologists that our present understanding of the brain and the mind of man is hardly more than a beginning of science it may be reassuring to recall that our task is the ultimate one. The problem of neurology is to understand man himself.— Dr. Wilder Penfield, 19651The human brain, at approximately three pounds with an esti-mated 86 billion neurons,2 is the most complex organ in the human body and arguably, the most complex structure in the known uni-
verse. It controls all processes in the body, from autonomic func-
tions that maintain life, such as heart rate and respiratory rate, to 
the ability to perceive and act on our environment. The brain is re-
sponsible for our emotions and thoughts, and enables us to learn, 
innovate, and create. It shapes our awareness of time and space, and 
of others and ourselves, and ultimately makes us human. Unsur-
prisingly, disorders of the brain can be deadly or severely debilitat-
ing for patients, their families, and society.
Although our current understanding of the human brain and 
mind is indeed “hardly more than a beginning of science,” techno-
logical developments over the past fifty years have enabled many 
problems in neuroscience to be approached. For example, advances 
in functional genomics and the ability to sequence the entire human 
genome have enabled scientists to characterize neuronal diversity 
at the molecular level, identify genes that contribute to disease, and 
examine fundamental principles of neurobiology.3 Optogenetics has 
provided neuroscientists with a tool for manipulating specific neu-
ronal activity to study the neural circuits that underlie behavior.4 
With regard to investigating human brain function and dysfunction, 
functional magnetic resonance imaging (fMRI) has undoubtedly 
become the method of choice due to its noninvasive nature, rela-
tively high spatial resolution, and ability to image the whole brain.5 
Supported by basic science, clinical neuroscience seeks to im-
prove our understanding of disease processes and guide preven-
tion, diagnosis, and treatment. Notably, insights into the neural ba-
sis of cognition, emotion, and social behaviour have the potential 
to transform how psychiatric disorders are diagnosed and treated. 
Accordingly, the U.S. National Institute of Mental Health launched 
the Research Domain Criteria project five years ago to help reframe 
mental disorders as brain disorders based on genetics, neural cir-
cuits, behaviour, and symptoms.6 Knowledge of brain function can 
also be translated into effective interventions. As an example, deep 
brain stimulation has become an established therapy for the man-
agement of Parkinson’s disease, tremor, and dystonia, and is being 
investigated for the treatment of psychiatric disorders such as ob-
sessive-compulsive disorder and treatment-resistant depression.7 
Beyond the scientific and medical community, brain re-
search has received considerable attention from politicians, 
governments, and the general public. In 2013, two major brain 
research projects — the European Commission’s Human Brain 
Project and U.S. President Barack Obama’s Brain Research 
Through Advancing Innovative Neurotechnologies (BRAIN) 
Initiative — were independently announced with the goal of 
ultimately understanding how the brain works.8 Overall, the in-
fluence of neuroscience on society can readily be seen in mass 
media, literature, and film.9 Last year, the discovery of neurons 
that encode spatial location and enable spatial navigation (ie the 
“brain’s GPS”) was celebrated with the Nobel Prize in Physiology 
and Medicine.10 
In this issue, the UWOMJ would like to celebrate the brain 
and mind, and provide a glimpse at the current state of neurosci-
ence in science, medicine, and society. A lot has changed since 
the time of Wilder Penfield, and although neuroscience is still 
in its infancy, current research and discoveries bring us closer to 
understanding the mysteries of the brain and mind, and human 
nature itself.
Jason L. Chan
Editor in Chief
Mysteries of the brain and mind
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abstract
Background: Clinical empathy has been repeatedly shown 
to increase patient satisfaction and improve clinical outcomes; 
therefore it forms an important cornerstone of the physician-pa-
tient therapeutic relationship. While some studies have shown 
that empathy in medical students decreases over the course of 
their education, other studies have contested these findings.
Purpose: This paper reviews studies and relevant litera-
ture in order to explore the relationship between medical ed-
ucation and clinical empathy, and in particular, the difference 
in results between those studies that demonstrated a decline in 
clinical empathy and those studies that did not.
Conclusion: Study design and methodology, differences 
in clinical culture, and differences in curriculum were identi-
fied as three possible influences that explain the lack of con-
sensus in the literature. This paper recommends a twofold 
approach to further research in the field of clinical empathy 
development. First, future studies examining this phenomenon 
should focus on longitudinal designs that incorporate objective 
measures and patient factors rather than relying exclusively on 
cross-sectional studies utilising self-assessment. Second, med-
ical schools should be encouraged to adopt or develop tech-
niques to assess the clinical empathy of their students and im-
plement solutions to mitigate a decline in empathy if required.
introduction
Clinical empathy, or “the ability of the physician to understand 
a patient’s experience, to communicate and confirm the under-
standing with the patient and then to act in a helpful and/or ther-
apeutic manner”,1 is central to fostering therapeutic relationships 
with patients and their support network.2 Literature reviews in-
dicate that empathy positively impacts patient satisfaction,3–5 de-
creases perceived distress and ultimately leads to improved clinical 
outcomes.5,6 Moreover, empathetic physicians encourage patient 
disclosure of symptoms leading to enhanced diagnostics4,7 as well 
as improved adherence.3–5 Conversely, a lack of empathy has been 
shown to have negative effects on patient care.8
Unfortunately, several cross-sectional and longitudinal studies 
following medical students through their years of study demon-
strate that medical students show a decline in self-reported em-
pathy, most noticeably after their clerkship year and continuing 
through residency.6,7,9–11 On the other hand, studies confirming an 
empathy decline during medical education seem to be localised to 
the Americas, as cross-sectional studies conducted in Iran12 and 
Pakistan4 find no variation in empathy based on student year, and 
studies in Japan,13 Korea14 and Portugal5 find an increase between 
early and later year students. These studies may cast doubt on the 
notion that empathy declines over the course of medical education, 
but they also point to cultural or curriculum-based factors that may 
explain the difference in results.
Given the importance of empathy in physician-patient encoun-
ters, and given the uncertainty in the literature concerning the na-
ture and severity of the alleged decline of empathy in medical stu-
dents, this paper will evaluate the research to assess whether or not 
clinical empathy is at risk of decline in medical students.
evaluation of the research
Analysis of the available literature revealed three main themes 
which may be contributing to the lack of consensus regarding em-
pathy decline in medical students: study design and methodology, 
differences in clinical culture, and differences in curriculum. Les-
sons learned from these areas may strengthen study methodology 
and may be used to enhance medical curriculum where necessary.
Study Design and Methodology
Any discussion regarding empathy is complicated by the am-
biguity of the term; this has made the relevant research difficult 
to navigate15 and created challenges when designing psychometric 
tools to measure it. In developing such measures, one must consid-
er the threats to construct validity that can arise due to variations in 
how cultural communities define empathy.12–14,16
For example, it has been suggested that Japanese social cues 
rely less on gestures and facial expressions when compared to their 
American counterparts,13 and as such, some standards of empathic 
communication may not be perfectly translatable cross-culturally. 
Great care must be taken in developing tools so that they account 
for such differences.
It is worth noting that the studies that did not demonstrate a 
decline were cross-sectional in nature, and could be subject to co-
hort effects; longitudinal studies following a class of medical stu-
dents throughout their education would provide a more robust data 
set from which to draw further conclusions.4,5,13
Finally, all of the studies in question utilised self-report ques-
tionnaires and many used a version of the Jefferson Scale of Phy-
sician Empathy (JSPE) to construct those questionnaires. Even 
though the JSPE was designed specifically to measure clinical 
empathy, and has been reported to correlate with patient/observer 
scores, one must consider the role of social desirability bias when 
interpreting self-reported results.4,14,17
Differences in Clinical Culture
Both physician and patient expectations play an important role 
when measuring clinical empathy. For example, there is much in 
Care and curriculum
Does clinical empathy decline during medical education?
Victor Parchment (BA Candidate), Naomi Mudachi (Meds 2017)
Faculty Reviewer:  Dr Barry Schwartz, DDS, MHSc (Division of Practice Administration)
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the literature to suggest that patients acclimatized to an East Asian 
clinical context are more comfortable sharing a vertical relation-
ship with their physician than their American counterparts, who 
may view such an arrangement as showing a lack of empathy.14,18 
Behaviour in one cultural context may be seen as lacking empathy 
while the same behaviour in another may be considered satisfac-
tory or laudable. More work needs to be done understanding the 
cultural differences in patient expectations before interventions 
can be designed; interventions that may increase a patient’s feel-
ing of physician empathy in a traditional American context might 
instead create the appearance of “uncertainty, lack of competence, 
and weakness”18 in a traditional Japanese or Korean context. This 
is of particular note when patients carry their expectations across 
borders, and physicians must be aware of their own cultural expec-
tations, as well as those of their patient.
Interestingly, baseline empathy scores for medical students 
were lower in the Japanese and Korean studies, compared with 
American and Italian medical students.18 While the Japanese and 
Korean students showed an increase in clinical empathy throughout 
medical education, physicians from these populations scored lower 
on empathy measures overall than physicians from the American 
and Italian populations. Though outside the scope of this paper, it 
would be worth investigating the shift of both groups compared to 
their respective general populations to better understand the rela-
tionship between cultural factors and clinical empathy.
The clinical culture of subspecialties can also influence em-
pathy decline. In the studies where a decline was noted, students 
that indicated a preference for people-oriented specialties (eg fam-
ily medicine, internal medicine and psychiatry) had higher levels 
of empathy at admission and experienced less decline in empathy 
than those who gravitated towards technology-based specialties (eg 
radiology and surgery).10,17,19 This difference may be related to the 
emphasis that people-oriented specialties place on interpersonal 
communication, which may reduce patient objectification.20 An-
other related factor may be the increased reliance on technology in 
certain fields, which shifts the focus from patients to test results.18,21
Differences in Curriculum
Each of the aforementioned studies focused on a single school, 
and thus the results may not be generalisable to all schools of that 
country or region. It has also been suggested that the academic cul-
ture of a school itself may play a role in the results obtained. For 
example, a highly competitive school with an emphasis on research 
may attract certain types of students, thus skewing the baseline re-
sults. This may have been the case in the study conducted at Seoul-
National University College of Medicine (SNUCM), which is one of 
the top-ranking medical schools in Korea.14
Curriculum itself may play a role in fostering clinical empathy. 
The second year students evaluated during the study conducted in 
Pakistan received more patient interaction, history-taking training 
and examinations designed to evaluate professionalism than their 
American counterparts,4 and professionalism has been shown to be 
positively correlated with clinical empathy.22 This is not an isolated 
effect: of the four studies that do not show a decline, all have simi-
lar curriculum profiles in regard to patient-centred and humanistic 
training. For example, third year students at SNUCM are required to 
take psychiatric courses and higher empathy scores in the following 
year may be a result of techniques learned during these courses.14 
The first and second year students surveyed at Okayama University 
in Japan spent only one day a week studying medical science while 
the rest of the curriculum was focused on other subjects from the 
arts and humanities; this early academic diversification may con-
tribute to the eventual rise of their empathy scores later in their 
academic careers.13 Lastly, students surveyed in the Portuguese 
study were exposed to a curriculum emphasising patient-centred 
healthcare, humanities training, interpersonal communication 
skills, clerkships in urban, sub-urban and rural communities, and 
frequent assessments of professionalism.5
Based on their study of medical students at the University of 
the West Indies, Youssef et al (2014) theorised that a decline in em-
pathy during later years may be attributable to an increase in stress 
caused by novel challenges that typically arise during this period 
of study.23 This theory correlates well with a study by Brazeau et al 
(2010) that demonstrated a link between medical student burnout 
and lower empathy scores.22 This indicates a potential point of cur-
ricular intervention for schools noting a decline in the empathy of 
their students over time.
prescriptions and conclusions
Based on the evidence that we have presented here, whether 
or not a study demonstrates a decline in empathy appears to be in-
fluenced by the sampling/study methodology used as well as the 
clinical culture and curriculum to which students are exposed.
The first way to approach these findings is to focus on im-
proving the tools and methodology underlying clinical empathy 
research. Some improvements could include using controlled or 
randomised controlled studies, utilising longitudinal designs, mea-
suring patient factors or skills-based outcomes rather than relying 
solely on self-assessment, and incorporating objective measures 
from the patient perspective to assess whether results are reflec-
tive of future performance (eg 10-item Consultation and Relational 
Empathy questionnaire).3,6,24 Critically, psychometric tools such as 
the JSPE must continue to be validated cross-culturally and against 
other established measures to ensure the data collected is reliable 
and predictive.
The second way to approach these results is from an institu-
tional perspective. Since few contest the value of clinical empathy, 
the goal should be using robust tools to: measure empathy at the 
institutional level, analyse potential weaknesses in the curriculum, 
and validate interventions designed to increase empathy. It is likely 
that curriculum and the wider clinical culture influence whether 
or not empathy declines, remains unchanged, or increases; there-
fore medical schools experiencing a decline should look to schools 
where such a decline is not present for methods to manage and en-
hance the clinical empathy of their students.
While the data on empathy change in medical students does 
not currently allow for definitive conclusions, further research will 
not only provide greater insight into this phenomenon, but also 
raise awareness of the importance of clinical empathy for future 
physicians.
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abstract
Ischemic stroke causes morbidity and death in 55 000 Cana-
dians each year.  While acute supportive therapy is essential for 
stabilizing ischemic stroke patients, resolution of cerebrovascular 
occlusion can only be accomplished by injection of thrombolytic 
agents. However, older guidelines restrict thrombolysis to within 
the first 3 hours of symptom onset. This short window of oppor-
tunity for thrombolytic treatment is complicated by its inherent 
adverse reactions, making it necessary to readily identify poten-
tial stroke cases, but also to diagnose accurately to avoid inappro-
priate treatment.  In light of statistics that identify late presenta-
tion as the most common reason for stroke patients not to receive 
thrombolytic treatment, and meta-analyses that now show ben-
efits of thrombolytic treatment up to 6 hours after stroke onset, 
guidelines are undergoing revision to allow larger treatment win-
dows.  This, along with continuing improvements in stroke treat-
ment access and infrastructure, will hopefully lead to better out-
looks for Canadians who suffer ischemic stroke.
It is not just a cliché: every minute really does count. On aver-
age, 1.9 million neurons, 14 billion synapses, and 12 kilometers of 
myelinated fibres are destroyed every 60 seconds following a large 
vessel ischemic stroke. Reminiscent of Christopher Nolan’s Inter-
stellar, the ischemic brain can age 3.6 years for every hour that a ce-
rebral artery is left occluded.1 Unfortunately, this is not just fiction. 
Ischemic stroke is a leading cause of death and disability, a crippling 
reality for 55 000 patients across Canada every year.2 While pre-
vention is crucial, therapeutic options are especially effective when 
prompt thrombolytic intervention is possible. Given the time-sensi-
tive nature of stroke management, it is important to be familiar with 
the general approach to acute stroke. We will focus on thrombolytic 
therapy for ischemic stroke but first, we will review the key points 
of stroke diagnosis.
diagnosis
History and physical examination offer vital information when 
an ischemic stroke is suspected. Usually, presentation will include 
a history of sudden onset focal neurological symptoms (Table), 
though symptoms may fluctuate in severity or worsen gradually. 
Headaches will occur in approximately 1 in 4 cases of stroke. For 
determining treatment options, the time of symptom onset is a crit-
ical feature of the history and should be detailed whenever possible. 
Ischemic stroke often occurs without pain, so many patients may 
not be woken by a stroke that occurs during sleep. In this case, it 
is assumed that the stroke began at the last time the patient was 
known to be symptom-free. Most presenting patients are alert, 
though infarction of the brainstem can cause a decreased level of 
consciousness. Nausea and vomiting may also occur if the brain 
stem is affected.3 
As many as 1 out of 8 initial diagnoses of stroke may be incor-
rect, so it is important to consider all of the possible mimics.4,5 Many 
of these mimics will tend to have more global presentations than 
most strokes, although the opposite is sometimes true.3 For exam-
ple, vertigo can often present with nausea and ataxia, mimicking 
the presentation of a stroke, particularly vertebrobasilar ischemia.4 
However, vertebrobasilar ischemia is more likely to present with 
cranial nerve deficits, such as loss of corneal sting sensation and 
loss of nasal tickle, and other focal symptoms (eg diplopia, dysar-
thria, hemianopsia, transient global amnesia). One of the most com-
mon non-stroke referrals to stroke teams is syncope due to suspi-
cion of brain stem ischemia, for which assessment for arrhythmias 
and excessive parasympathetic stimulation can rule out more com-
mon causes of syncope.  Of all stroke mimics, unrecognized seizures 
followed by post-ictal paralysis or confusion may be the most com-
mon.4,5 Vigilance for a history of epilepsy and signs of seizure ac-
tivity  would direct appropriate investigations including electroen-
cephalography. Other mimics include metabolic abnormalities (eg 
hypoglycemia, hepatic encephalopathy), drug overdose, neoplasia, 
and infection, which can be evaluated for with routine laboratory 
tests.3,4
Clinical evaluation can help differentiate hemorrhagic and 
ischemic strokes. Intracranial hemorrhage is more likely with the 
presence of coma on arrival, vomiting, severe headache, current 
anticoagulation therapy, hypertension, or non-diabetic hypergly-
cemia. However, imaging studies are still necessary to confidently 
rule out a hemorrhagic stroke or other vascular brain lesions.4 The 
current standard of imaging is noncontrast-enhanced CT, owing 
to the scan’s speed, availability, and relatively low cost. The target 
timeframe for diagnosis of stroke patients is to complete CT exam-
ination within 25 minutes of arrival, with interpretation complete 
by the 45 minute mark from arrival.6 Laboratory tests should also 
be complete by this time and to ensure this kind of efficiency, stroke 
centres have to implement appropriate infrastructure. 
general support & thrombolytic therapy
Acute ischemic stroke can lead to rapid patient destabilization, 
even without initial overt failure of vital function, so protective 
measures are imperative for the recovery of stroke patients. This 
includes monitoring oxygen saturation with a pulse oximeter and 
clinical procedures
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providing oxygen supplementation as needed to maintain ≥95% 
O2 saturation. Endotracheal intubation and careful monitoring of 
respiratory function may also be indicated if there is suspicion of 
brainstem ischemia or compression.7 Myocardial infarction and 
cardiac arrhythmias may develop secondary to stroke, and a 12-
lead ECG should be monitored for all stroke patients.3 Fever devel-
opment after stroke onset is a poor prognostic factor, and studies 
indicate that this should be treated with antipyretics and cooling 
devices.8 Induced hypothermia has been theorized to be neuropro-
tective, but evidence to support this approach is still indefinite.9,10,11
The specific goal for thrombolysis and subsequent brain tissue 
reperfusion is to salvage tissue in the ischemic penumbra—tissue 
surrounding the ischemic core that has not been yet been infarct-
ed.3 This is accomplished with rapid intravenous administration 
of recombinant tissue plasminogen activator (rtPA), powerful 
thrombolytic agents that accelerate the breakdown of the fibrin 
meshwork of offending thromboemboli. Several drugs belong to 
the serine protease class of rtPA (alteplase, reteplase, tenecteplase), 
and all cleave endogenous plasminogen to its active form, plasmin, 
which degrades fibrin. With intravenous administration of throm-
bolytics, 37% of patients in Canadian hospitals achieve excellent 
clinical outcomes (n = 1135).12 In comparison, only 27% of ischemic 
stroke patients would be expected to achieve this level of recovery 
on standard therapy without thrombolysis.12,13 Excellent outcome 
was defined as a return to the level of function prior to stroke, as 
assessed by the modified Rankin Scale. Since these drugs are so ef-
fective at dissolving blood clots, they come with very serious risks 
of hemorrhage, including intracranial hemorrhage. This is especial-
ly of concern with hemorrhagic stroke, but it is also a consideration 
in the treatment of ischemic stroke due to danger of conversion to 
intracranial hemorrhage. Understandably, active or recent bleeding 
are contraindications for thrombolytic therapy. Aspirin or other an-
ticoagulants should not be given at the same time as thrombolytic 
therapy, as they increase the risk of bleeding.14 
looking forward
Ongoing trials are investigating refinements to thrombolytic 
therapy, and the literature is very extensive and sometimes polar-
ized. Many thrombolytics have been developed in an attempt to 
improve therapeutic benefit, to expand the window of opportunity 
for drug administration, and to reduce the rate of adverse events, 
namely hemorrhage. New drug candidates are often theorized to 
improve thrombolytic therapy because of increased biological half-
life or improved target specificity. However, a Cochrane meta-anal-
ysis did not find adequate evidence to indicate any superior alter-
native to alteplase (0.9 mg/kg), the only FDA approved agent that is 
indicated for acute ischemic stroke.15 Similarly, intraarterial throm-
bolytic administration was theorized to reduce adverse events be-
cause of more localized delivery and lower therapeutic doses, but 
this was also found to be unsupported.15 The potential advantage of 
intraarterial over intravenous administration may be offset by the 
delay in drug delivery because of relative procedural difficulty. 
Although initial clinical trials on thrombolytic therapy found 
unfavourable outcomes in patients greater than 80 years of age and 
patients that have had symptoms for longer than 3 hours, more re-
cent studies have had success with expanded inclusion criteria. The 
most recent Cochrane review suggests patients older than 80 years 
equally benefited from thrombolysis, and while treatment within 
3 hours is still far more optimal in all age groups (OR 0.66, 95% CI 
[0.56 – 0.79], n = 2187), treatment within 6 hours still significant-
ly reduced death or dependency (OR 0.84, 95% CI [0.77 – 0.93], n 
= 6729).14 Unchanged since 2001, The Canadian Asssociation of 
Emergency Physicians still recommends rtPA treatment within 
3 hours only, while the 2010 Canadian Best Practice Recommen-
dations for Stroke Care indicate that rtPA can be given within 4.5 
hours of symptom onset.16,17 Centres involved in thrombolysis pro-
tocol research may expand the window for treatment, so differenc-
es should be expected. London Health Sciences Centre currently 
offers rtPA treatment within 4.5 hours of symptom onset to patients 
of any age. 
Despite the advances in patient outcomes, only 6.1% of isch-
emic stroke patients received thrombolysis throughout Canada’s 
provinces in 2008-2009 (n = 9588). The territories were excluded in 
this study, leaving us only to speculate on the challenges for stroke 
management in these regions. Rates for utilization of thrombolyt-
ic agents were variable: comprehensive stroke centres treated 11% 
of ischemic stroke cases with thrombolysis, compared to 5.7% in 
primary stroke centres, and just 1.0% in other centres. In this same 
study, the reasons documented for not treating with thrombolysis 
included patients presenting too late in 42% of cases, neurological 
deficit too mild in 24%, clear medical contraindication in 5%, and 
no reason was documented in 25%.18 While refining the eligibility 
criteria for rtPA treatment is important, these variable utilization 
clinical procedures
Table: Common patterns of focal neurological impairments correlated to 
region of infarcta
Dominant (left) hemisphere • Aphasia
• Contralateral hemiparesis, sensory loss, 
spatial neglect, homonymous hemianopia, 
impaired conjugate gaze
Nondominant hemisphere • Contralateral hemiparesis, sensory loss, 
spatial neglect, homonymous hemianopia, 
impaired conjugate gaze
Subcortical & brain stem • Unilateral hemiparesis, sensory loss
• Dysarthria
• Absent abnormalities of cognition, lan-
guage or vision
Brain stem • Motor or sensory loss in all four limbs
• Crossed signs (ipsilateral cranial nerve & 
contralateral spinal deficits)
• Dysconjugate gaze
• Nystagmus
• Ataxia
• Dysarthria, dysphagia
Cerebellum • Ipsilateral limb ataxia
• Gait ataxia
a Adapted from Adams et al.3
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rates indicate that serious infrastructure improvements will also 
have to be made in our ability to identify and respond to ischemic 
stroke events. With prompt identification and management, further 
improvements in thrombolysis, and national coordination of stroke 
care, we can look forward to better prognoses for acute ischemic 
stroke. 
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introduction
Since the turn of 21st century, improvements in medical imag-
ing have been considered one the greatest triumphs in the history 
of modern medicine. Advancements in magnetic resonance imaging 
(MRI) have allowed physicians to peer into human anatomy with 
ever greater resolution. MRI works through the magnetization 
of hydrogen protons in the body followed by short bursts of radio 
waves which are reemitted and subsequently detected for noninva-
sive neuroimaging. However, this technique was limited to forming 
static structural images without providing real-time information on 
brain activity or function. 
Blood-oxygen-level-dependent (BOLD) MRI, also known as 
functional MRI (fMRI), overcomes these limitations and enables 
physicians to visualize the activity of the brain.1 Changes in blood 
flow act as a marker for metabolic activity and thus neuronal firing, 
as blood flow increases to more active regions. BOLD was first de-
veloped in 1989 and demonstrated that deoxyhemoglobin (a natural 
paramagnetic substance) could act as contrast agent.2 In this article, 
we will review the advantages and limitations of fMRI, while intro-
ducing some developments in the field.
indications
Currently, fMRI is mainly used for research purposes but there 
are a growing number of specialized clinical indications. For exam-
ple, prior to neurosurgery fMRI may be used to map critical areas 
of the brain such as the language centres.3 It can also be used to 
assess brain function of patients with seizures.4 Some studies in-
dicate that fMRI remains promising for use as a detection tool for 
the diagnosis of early Alzheimer’s disease.5,6 This technology may 
also have wide-ranging applications for common psychiatric disor-
ders. Patients with major depressive disorder, schizophrenia, atten-
tion-deficit hyperactivity disorder and autism were distinguished 
from the resting state of controls using BOLD imaging.7-10
However, brain activity is often variable, so clinical interpreta-
tion given the patient’s context is essential. Clinicians should also 
consider the effect of sedation, medications and anxiety on the he-
modynamic response and subsequent signal. fMRI can also be dan-
gerous for people with pacemakers and metal valves. Nevertheless, 
as a fairly young technology, fMRI and its variants have the poten-
tial to become a gold standard imaging tool in neuro-medicine.1
advantages
When compared to other non-invasive functional imaging 
techniques, the central advantage of fMRI is its high spatial res-
olution in the millimeter and potentially submillimeter range.11,12 
Its ability to distinguish between smaller regions of activity is su-
perior to positrom emission tomography (PET) and much greater 
than magnetoencephalography (MEG) or electroencephalography 
(EEG), which have spatial resolution on the order of centimeters.13 
Although seemingly insignificant, such a difference in resolution is 
vast considering that a few square millimeters of grey matter may 
contain millions of neurons, constituting billions of synaptic con-
nections. 
fMRI can also detect activity deep inside the brain in three di-
mensional space, while EEGs generally reflect global neural activ-
ity on the cortical surface. Compared to PET, BOLD imaging does 
not require radioactive contrast agents or metabolites and provides 
higher temporal resolution.14 Thus, it is a relatively safe imaging 
tool, even for children and pregnant women. Along with advance-
ments in computational software, multivariate analysis in fMRI al-
lows many small units of the brain to be tracked in unison, without 
simply averaging the activity of whole brain regions together.1 In-
stead of having large areas of average brain activity, the use of these 
three-dimensional pixels (voxels) allows for greater spatial resolu-
tion and reduced noise. 
The critical assumption that hemodynamic response indicates 
neuronal activity has been questioned, yet there is a great deal of 
evidence that supports the validity of blood-oxygen-dependent im-
aging. Electrode implants have confirmed that neuronal activation 
correlates with BOLD MRI recordings.15 Similarly, recent advanc-
es in optogenetics have allowed the activation of specific neuronal 
circuits that have also been found to match the fMRI signal.16,17 Al-
though the scanners themselves are costly, they are common and 
the same platform can be used for both functional and anatomic 
imaging.14
limitations
Despite being correlated with the electrical activity of neu-
rons, fMRI is an indirect imaging method. Often studies are able 
to demonstrate correlation of a brain region with a given task or 
condition but cannot establish causation. Subtle small-scale chang-
es in neuronal activity likely go undetected as they do not induce a 
significant change in blood flow, while routine hemodynamic vari-
ations may generate noise.14 fMRI cannot distinguish the number 
of neurons firing. A hypothetical circuit may have excitatory and 
inhibitory signals that cancel out, but this would only be detected 
as generalized neuronal activity. 
Hemodynamic responses are inherently slower than electro-
chemical ones, which can be detected by MEG/EEG in the millisec-
ond range.13 The temporal resolution of fMRI being on the order of 
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2-3 seconds means that the technique is not truly real-time.18 More-
over, there is generally a trade-off between spatial and temporal 
resolution since it takes more time to acquire images with smaller 
voxels.14
In addition, the interpretation of fMRI is statistically demand-
ing. The use of different statistical techniques can lead to subjective 
interpretations. Correction for multiple comparisons is absolutely 
necessary to reduce false positives. One humorous study demon-
strated false-positive brain activity in a dead salmon when multiple 
comparison corrections were not made.19 
Finally, there are currently few studies for practical clinical 
use, although research is actively being conducted in this area. To 
obtain higher resolution, MRIs with stronger magnetic fields are 
being developed. Although the genotoxic effects of a static mag-
netic field have been demonstrated at the cellular level, they are 
thought to be negligible.20
new developments
The basis of fMRI is to track brain function using a surrogate 
marker that can be detected by MRI. Thus, one avenue being ex-
plored has been to develop newer and safer intravenous contrast 
agents that allow sharper resolution and faster image acquisition 
compared to the oxygenation state of hemoglobin used by BOLD 
MRI. However, the benefit of these agents has not been firmly es-
tablished in humans yet. 
From a clinical perspective, clinician-scientists are also em-
ploying fMRI in new ways to help patients. For example, research-
ers at the Robarts Institute (Schulich School of Medicine & Den-
tistry, Western University) are using fMRI to communicate with 
patients in vegetative states.21 Moreover, fMRI has the potential to 
become a diagnostic test to assess patients with hypoxic-ischemic 
brain injury, perhaps even providing a new method to determine 
brain death. 
Another development is to use multiple modalities simulta-
neously to map activity in the brain. One of these combinatorial 
approaches is the EEG-fMRI.22 Researchers have been able to use 
fMRI to guide EEG signal acquisition to map the electrical activity 
of neurons in three-dimensional space. The challenge with mul-
timodal imaging techniques arises when trying to find a suitable 
method to synthesize and interpret information from the two very 
different imaging tools. 
conclusion
Since it was first described by Ogawa et al, fMRI technology 
has rapidly developed as a noninvasive method to map brain activi-
ty. While it remains for the most part a research tool, fMRI has great 
potential to become widely adopted in clinical medicine. Already, 
practical applications such as localizing key brain regions prior to 
surgery exist. With advancements in MRI technology and increases 
in computational power, fMRI will be an important player in the 
field of neuroimaging in the future.
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introduction
Advances in neuroscience and biotechnology in recent decades 
have opened up unprecedented possibilities for altering and mod-
ifying the human brain to enhance cognitive and mental functions. 
Although one gets the impression that much of the current neuro-
science research in “mind enhancement” is still only nascent, in the 
case of certain studies it is already possible to see clearly their im-
plications for—and consequently their challenges to—some of our 
current medical, legal and cultural conventions. Take, for instance, 
the example of recent research in a neuroscience field called op-
togenetics. In 2013, a group of neuroscientists developed a way of 
inducing a “false memory” in experimental mice. These research-
ers had identified a specific population of neurons in the dentate 
gyrus of an animal subject’s hippocampus, known to be involved in 
memory formation and storage, that was naturally activated when-
ever the animal was exposed to painful stimulus (eg electric shock). 
These neurons would be reactivated in the future in response to the 
same or similar context, even in absence of the painful stimulus, 
producing a fear response—that is, because a “fear memory” had 
been formed. By reactivating these same cells artificially (using 
light energy—hence the name, optogenetics) in a different context 
than the one used to condition the original fear memory, the fear 
response could again be elicited in the animal subject, this time to 
an entirely new context—thus forming a “false memory.”1 If extrap-
olated to the human brain, these and similar discoveries in nano-
technology, biotechnology, information technology, and cognitive 
science (NBIC), open up exciting and in some cases potentially 
alarming new possibilities. The imaginable applications of such 
techniques span a spectrum, from medical therapies that could 
cure individuals traumatized by abuse to the ominous spectre of 
a government reprogramming the minds of criminals and perhaps 
political dissidents. 
cognitive liberty
Recently, an attempt has been made to confront the issue of 
NBIC technology as a moral-philosophical problem by articulating 
the novel ethical concept of “cognitive liberty.” According to Sen-
tentia, a leading neuroethicist on this subject, cognitive liberty is 
the idea that every person has a fundamental right not only to think 
independently (a right already contained in liberalism’s commit-
ment to ‘freedom of thought,’ as defended by J. S. Mill), but also 
“to have autonomy over his or her own brain chemistry.” It would 
seem to follow that, as a fundamental right, cognitive liberty would 
require strong legal protections for the private use of neuroen-
hancement (NE) technologies.2 This view of cognitive liberty as a 
fundamental right directly challenges a number of contemporary 
norms. For instance, it seems to imply the need to protect the recre-
ational use of psychotropic drugs, a practice that is currently illegal 
in many places.
From a philosophical standpoint, there are opposing stanc-
es on how NE shapes the definition of being a self: the essential-
ist viewpoint that NE compromises what it means to be a person, 
and the existentialist opinion that NE is a choice people can make 
as the agents of their own development. According to theologian 
Alan Watts, there is a longstanding view within Western culture of 
the person as an “individual, self-determining, responsible ego.”3 
Essentialists would argue that NE jeopardizes this definition of 
personhood and compromises the “authenticity of persons” by in-
terfering with individuals’ natural journey of self-discovery and 
personal growth.4 Individuals might confuse their understanding 
of themselves as they are with that of their neuroenhanced selves. 
Conversely, existentialists would support NE, as they believe that 
acting as the responsible agent of one’s development is a fundamen-
tal part of being a person. It follows that actively shaping who one 
wants to be includes how one wants to think, under the influence 
of NE or not. So long as these NE interventions pose low risk to 
health, should individuals not have the right to benefit from their 
enhancing effects?3 
Ethical issues of cognitive liberty also concern the social im-
pact of NE. On one hand, society as a whole might benefit from 
NBIC-related medical innovation; thus, one could argue that there 
is an obligation to pursue research into NBIC-related technologies 
such as optogenetics. Yet one might also have reason to fear that 
unequal access to memory- and attention-improving tools could in-
crease social inequality within our society. In an era of competitive 
job markets and information overload, those who can access and af-
ford NE may be perceived as having an unfair advantage over those 
who cannot. Ethicists have raised concerns over how increasing the 
standard of cognitive fitness within such a competitive environ-
ment might actually impede rather than enhance cognitive liberty, 
as non-users will feel pressured to use NE in order to keep up with 
their cognitively advantaged peers.4
legal and social dimensions
Cognitive liberty is implicit in the freedoms of thought and 
action.3,4 However, proponents of NE argue that cognitive liberty 
and its boundaries must be explicitly defined within positive law 
in order for individuals to be protected in their elective use of NE 
and protected from government imposition of NE.3 Proponents of 
Cognitive liberty
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elective NE use would argue that the value society places on bodily 
integrity (the autonomy of persons over their own bodies) supports 
the legal right to cognitive liberty.5 Our legal system allows individ-
uals to engage in behaviours that put the physical body at risk, such 
as extreme sports. Instead of prohibiting these activities, regula-
tions are put in place to ensure safety and informed consent, and 
the onus is placed on the individual to determine whether the be-
haviour is appropriate.4 Given that individuals are allowed to make 
informed decisions regarding behaviours with potential physical 
harms, how can behaviours with neurologic effects be criminal-
ized? After all, the nervous system is part of the physical body. This 
question is especially relevant to NE with low risk-profiles, as the 
harm principle, which states that power cannot be exercised against 
a civilized community’s will unless it is to prevent harm, is a pre-
cursor to criminalization.3,6 The counterargument to this notion is 
that mind and body are distinct, as are our understandings of these 
entities. Injury to the body is well researched, whereas the defini-
tion of “illegitimate mental harm” remains unclear.4 Critics of NE 
would argue that it is counterintuitive to draft policies in support of 
NE while our understanding of the mind remains limited and fully 
informed decisions about its use cannot be made. Nevertheless, as 
our knowledge of brain function is expanding, policy-makers must 
consider explicitly defining cognitive liberty within positive law in 
order to lay the foundations for safe and regulated use of NE in the 
future.2
Although no court has yet ruled on a cognitive liberty case, 
there are precedents in other areas of constitutional case law that 
help us predict how courts might decide on the question of cog-
nitive liberty in the future. Constitutional guarantees of individual 
rights in Canada and the United States strongly reflect the harm 
principle, yet the courts have not applied this principle in a consis-
tent or unqualified way. Rather, the courts have restricted individu-
al liberty in a wide range of areas of private life, such as prohibiting 
the recreational use of some drugs (methamphetamines) and not 
others (nicotine and alcohol); allowing the sex industry to exist, 
but banning prostitution; and allowing self-harm, but only up to a 
point—namely, not to the point of suicide. The reason for this is that 
the courts have recognized other principles enshrined in the law 
that are distinct from the harm principle. Section 1 of the Charter of 
Rights and Freedoms accepts that “reasonable limits” to fundamen-
tal individual freedoms may be prescribed by law in order to uphold 
a “free and democratic society,” and in accordance with this consti-
tutional provision the Supreme Court of Canada (in R. v Oakes) has 
established precedents for limiting individual freedoms as a way of 
defending “collective goals of fundamental importance.”7 Thus, for 
example, in 1993 the Canadian Supreme Court ruled in R. v. Trem-
blay, a case involving sex trade workers in Quebec, that the law may 
restrict individual liberty in accordance with a “community stan-
dard of tolerance”—in this case, for acts of “anti-social” indecency. 
The court considered this community standard to be a legitimate 
imposition on individual liberty that was consistent with a liberal 
constitution.8
In these and other such cases, the courts have recognized the 
need to balance the common good against individual autonomy, fol-
lowing a long tradition of democratic thought, from Aristotle up to 
the intellectual founders of the Anglo-American republic, that has 
understood a functioning political order as deriving at least some 
of its stability from a certain moral consensus or majority opinion—
whether that opinion is more enlightened, or less.9,10 The question, 
then, is whether it is likely that the majority moral opinion can now 
or will in the future be able to tolerate such practices—psychotropic 
drugs, optogenetic memory alteration, cognitive enhancement—as 
are defended by advocates of cognitive liberty. For now, it can only 
be said that it will likely be able to tolerate some (eg certain medical 
therapies), but not others (eg hallucinatory recreational drugs, or 
their NE equivalents). This is complicated by the possibility that 
the majority moral opinion of a community may change over time. 
Democratic regulation of NE will continue to be a challenge within 
our ever-evolving society.
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introduction
The word “altruism” is commonly ascribed to those who pur-
sue a career in healthcare. However, looking at medicine through 
the lens of altruism shuts our eyes to the inherent humanity of 
physicians and limits our ability to provide optimal care. It is un-
reasonable to expect that physicians will (whether consciously or 
unconsciously) always prioritize ideal health outcomes in the face 
of varying incentives. This is especially true given that there is no 
single universally accepted definition of what “ideal health out-
comes” would be. Unsurprisingly, a recent Cochrane review of the 
subject found that physician compensation models do in fact influ-
ence behavior.1 How then can we align physician incentives with 
quality care?
There are four discrete compensation structures in use, with 
a blend of these commonly employed. Fee-for-service (FFS) mod-
els compensate doctors a set amount for each service they perform. 
Capitation models offer compensation based on the total number 
of patients under a doctor’s care, regardless of how frequently each 
patient seeks care. Salary models offer physicians fixed remunera-
tion that does not vary based on the services they perform nor pa-
tient demographics and are commonly employed by hospitals and 
community health centers. Pay for performance (P4P) models pro-
vide direct financial incentives for meeting certain specific treat-
ment goals.2,3
In Canada, 40% of physicians primarily receive FFS payments 
(>90% of their income), 10% primarily receive salaried payments, 
and 1% primarily receive capitation compensation. 33% of physi-
cians receive a blend and about 16% receive the majority of their 
compensation through other forms, including P4P/incentives, 
short term contracts, and per diems.4
health outcomes
There are several key health outcomes which are affected di-
rectly by physician remuneration schemes. The most significant in-
clude quantity of patient visits, quality of patient care, efficiency of 
resource use, and physician acceptance of complex patients.2,3
The effect that a given compensation scheme has on health 
outcomes is closely correlated with the “variability” in remuner-
ation received, which is a representation of a physician’s control 
over their own income. FFS and P4P schemes are considered wide-
ly variable, while salaried systems are considered fixed. Capitation 
models fall somewhere in between, but generally produce out-
comes more in line with salary models.4 This establishes a spectrum 
by which we can compare the different models.
FFS models give physicians considerable control over their 
earning potential but in so doing create a mixed bag of externalities. 
It creates an incentive for physicians to provide a higher quantity of 
treatment to patients, as payment is dependent on the quantity de-
livered. FFS also incentivizes physicians to perform a high volume 
of procedures and tests that have greater fees attached to their pro-
vision. By extension, FFS unfortunately encourages the provision of 
unneeded investigations and treatments, undermining the princi-
ples of resource management, and potentially biasing physicians in 
favor of carrying out more expensive actions when a simpler option 
may suffice.5-7
Capitation models are perhaps the best at reinforcing the im-
portance of preventative medicine and resource management. 
However, this model does not offer additional remuneration for 
seeing the same patient multiple times, so a physician is uninten-
tionally rewarded for seeing a patient as little as possible. The result 
is an emphasis on prevention, the conservation of resources and the 
use of treatment plans that require little management and have few-
er side effects and complications. Potential negative consequences 
include an adverse impact on meaningful doctor-patient relation-
ships, and a decreased incentive to see the same patient multiple 
times (even when warranted) or accept complex cases.7-13
Salary models reimburse physicians independent of the num-
ber of patients they see, the amount of time spent with patients, and 
the type of services provided. Monetary incentives are significantly 
limited, so there is no financial motivation for a physician to work 
harder than the minimum or to conserve resources; however, on 
the positive side this also means there is no financial deterrent to 
spending more time with patients, taking on difficult patients, or 
utilizing more intensive and involved treatment regimes.5,14
P4P models seek to correct many of the problems inherent to 
FFS, capitation, and salary systems. Since 2002, Ontario has gradu-
ally introduced more P4P measures, particularly within the realm 
of family medicine. Such measures include incentives for providing 
monitoring tests to diabetics (HbA1c levels, cholesterol levels, and 
eye tests), administering flu shots to vulnerable populations, and 
many others. A recent Cochrane review showed that 6 of 7 pub-
lished studies on the effectiveness of P4P showed clear positive im-
pacts on patient outcomes.15 The actual magnitude of these impacts 
however were somewhat modest, and some research has pointed 
out that some specific types of P4P (for example those associated 
with mental health and drug abuse) are in need of optimization 
before they become cost-effective.16 Despite this, the effects when 
these incentives are fine-tuned and implemented on a broader scale 
are certainly worth investigating.   
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literature review
There are several studies that seek to quantifiably contrast 
physician compensation models. An analysis of family physician 
behavior showed that primarily-FFS physicians spent a mean 37 
hours seeing approximately 134 patients every week. In compari-
son, salaried physicians spent only 30 hours seeing 72 patients per 
week. Physicians compensated through capitation fell between 
these figures spending 33 hours seeing 96 patients. Thus, the less 
variable the payment scheme, the fewer hours worked and number 
of patients seen.18 
A study by Dumont (2008) showed that although the number 
of services provided was found to decrease with the rigidity of the 
payment scheme, the actual amount of time spent performing each 
service increased, supporting the notion that there may be an inher-
ent balancing of quantity versus quality across payment schemes.17 
Interestingly, salaried and mixed compensation physicians ap-
peared to use this extra time to pursue teaching or research inter-
ests, with a twofold propensity to engage in these activities com-
pared to FFS physicians.14
It was found that doctors operating under less variable pay-
ment schemes (eg salary) accepted more complex patients, in-
cluding Aboriginals, low income patients, and those suffering from 
substance abuse, mental health problems, and/or homelessness.5-11 
Salaried physicians saw 2–3 times more complex patients on aver-
age than FFS physicians, while mixed compensation physicians saw 
approximately 1.5–2 times more than FFS physicians.17
In a general sense, the literature supports the theory that more 
fixed models of compensation emphasize preventative care, follow-
ing the logic that healthier patients are seen less often, minimizing 
work for healthcare providers. Resource efficiency is also signifi-
cantly improved in more fixed models with fewer unnecessary con-
sults, procedures, and testing. However, more fixed models see a 
conspicuous decrease in number of patients seen and hours worked 
as a whole, as the financial incentive to be productive by that mea-
sure is no longer present.4
conclusion
 With some overlap, each system creates a host of beneficial 
and deleterious incentives for physician behaviour. The ideal com-
pensation structure would strike a fine balance between these 
behaviours in optimizing key health outcomes. This ideal model 
would motivate physicians to see a large enough number of patients 
to reduce barriers to access, but small enough to ensure each pa-
tient receives adequate time and attention. It would ensure doctors 
do not discriminate against patients for being too complex, and 
ensure the feasibility of spending lengthy amounts of time with 
patients who require it. It would also create strong incentives for 
efficient resource use, limiting the provision of unneeded services.   
Since the practice of any two doctors within the same specialty 
can vary widely, a rigid salary model is not a practical nor equitable 
choice for the majority of physicians. A salary model is likely only 
appropriate as a niche form of compensation for certain practice 
types like emergency physicians, rural doctors with a small patient 
base, and some academic physicians.  
Capitation, although forward-thinking in terms of prioritizing 
preventative care, encourages a potentially hazardous mindset—
undermining the doctor-patient relationship and decreasing the 
frequency of contact points with the healthcare system. Current 
data supports the notion that capitation may be better suited play-
ing a role as part of a blended arrangement than as a sole method of 
remuneration. 
In the short period of time P4P has been in use, it has been 
utilized largely as an experiment of limited scope, but the results of 
this experiment are quite promising.18-23 More research should be 
done to determine what services are in need of incentivizing, and 
what magnitude of incentive motivates behavioral shifts. A harmo-
nized FFS-P4P blend represents a tremendous opportunity to rev-
olutionize medical care.10,24,25 Change is always difficult, but such 
a change would likely be popular for both physicians who would 
gain increased autonomy and patients who would benefit from im-
proved outcomes. If Ontario could garner enough political capital 
to embrace such a change in policy, it has the opportunity to be-
come a leader in applying economic principles to the provision of 
medical services and quality care for patients and families.
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health promotion
disease burden: a changing landscape
Over the 85 years this journal has been publishing, medicine 
has adapted to the changing landscape that is disease burden. In 
1930, the majority of diseases that medicine fought were infectious 
in nature. Influenza, pneumonia, tuberculosis, and gastrointestinal 
infections were the top killers. After 85 years of scientific advance-
ment, infectious diseases have become well controlled in the de-
veloped world, and the population no longer fears these ailments. 
In 2015, different beasts threaten our lives—heart disease, cancers, 
and chronic airway diseases comprise the majority of our disease 
burden.1 Valar morghulis—all men must die. As medicine saved pa-
tients from acute conditions, they began living long enough to die 
from chronic diseases. As the disease burden shifted, so too did the 
attention and anxiety of the population, which in turn shifted one of 
the most important drivers of medical progress: funding.
a funding disparity
According to Jones and colleagues, the “goal [of medicine] should 
be an integrated policy under which health care and public health 
programs together fully address the disease burden,”1 This implies 
that funds should be allocated in proportion to the disease burden 
they represent; for example, since heart disease is the major con-
tributor to disease burden in North America, it should receive the 
greatest amount of funding. However, this is not the case. According 
to the NIH, while heart disease causes more deaths than any other 
disease, in 2006 it received only 3.3% of NIH funding ($398 mil-
lion), while HIV/AIDS, with a prevalence ten times lower, received 
seven times more (~$2.9 billion). The funding disparity is pervasive: 
together, HIV/AIDS, diabetes mellitus, perinatal conditions, demen-
tia, and alcohol abuse account for 49% of NIH research funds, but 
none of these conditions are listed in the top ten causes of mortality.2 
als ice bucket challenge – a case in point
This funding disparity extends beyond government funding 
to publicly raised charity funding. The most recent example of a 
disconnect between disease burden and funding raised through 
charitable donation is the viral phenomenon of the ALS Ice Buck-
et Challenge. Amyotrophic lateral sclerosis (ALS), also known as 
Lou Gehrig’s Disease for the baseball player who made it famous, 
is a progressive, incurable, neurodegenerative disorder causing 
muscle weakness and eventual death. It is the most common form 
of motor neuron disease and upon diagnosis, it has a median sur-
vival of 3-5 years. Prevalence rates range between 2.7 and 7.4 per 
100 000 across North America and Europe, with the disease being 
slightly more common in men (M:F ratio of 1.3-1.5:1).3
ALS recently made waves in the media through a viral fund-
raising campaign involving filming the dumping of a bucket of ice 
water on someone’s head in an effort to promote awareness of ALS 
and subsequently raise money for research. Most videos end with 
a challenge to others to follow suit. 
The phenomenon began in Florida in July 2014 when a local 
golfer, Chris Kennedy, was nominated to do the Ice Bucket Chal-
lenge or donate money to a charity that benefitted a local child 
with cancer. When Kennedy passed the challenge along, he chose 
a charity benefitting ALS because he had an afflicted relative. A 
video posted to YouTube on July 15, 2014 appears to be the first 
incidence of the Ice Bucket Challenge being connected to ALS. 
Through social media, the trend exploded and spread across coun-
tries and organizations.4
According to CBC, more than 260 000 Canadians took part 
in the Ice Bucket Challenge and raised over $16.2 million for ALS, 
~$10 million of which will go directly to research, and ~$6 million 
of which will go to supporting those living with ALS. The Cana-
dian government also contributed $10 million to ALS.5 This is un-
doubtedly an impactful contribution but the Ice Bucket Challenge 
is wrought with issues.
Paradoxically, the usual challenge is to perform the Ice Buck-
et Challenge within 24 hours or make a charitable contribution 
to ALS, in other words allowing people to forego donation if they 
complete the challenge. Many people throughout the campaign 
raised concerns, especially since every video showing the chal-
lenge being completed seemed to imply that dumping cold water 
on your head is preferable to donating to ALS. Several individuals 
suffering from ALS have also spoken out that the campaign re-
duces a debilitating and lethal disease to a social bandwagon onto 
which people eagerly jump without any real regard for its pur-
pose.6 However, there is a more worrisome issue at the heart of the 
ALS Ice Bucket Challenge.
According to Statistics Canada, the number of Canadians re-
porting charitable contributions on their income tax is decreasing 
(down 0.6% from 2010 to 2011), suggesting that fewer people are 
donating money to charity. However, the rise in charitable contri-
butions suggests that fewer people are donating more. Further, only 
15% of Canadian donations are to healthcare organizations, amount-
ing to $1.59 billion. Charitable donations are affected by economic 
conditions such as the recent economic downturn, suggesting that 
the surge in funding for ALS may represent an equal decrease in 
contributions to all other healthcare charities.7,8 This opportunity 
cost is the most troubling aspect of the Ice Bucket Challenge. 
What kills us and what costs us
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In 2011 (most recent data), 47 627 Canadians died of heart dis-
ease, accounting for 19.7% of deaths, yet the Canadian Heart and 
Stroke Foundation received only $114.5 million in fundraising do-
nations, equivalent to approximately $2404 per individual death.9,10 
By comparison, between 700 and 1100 Canadians die of ALS each 
year, while the Ice Bucket Challenge alone (not counting donations 
outside of the challenge) raised $16.2 million in Canada; equiva-
lent to between ~$16 200 and ~$23 150 per individual who died.5,11 
Moreover, economic costs due to cardiovascular disease in Canada 
in 2000 totaled $22.2 billion, representing 17% of all hospitaliza-
tions (2005-2006) and 10% of all visits to community physicians 
(2007).12 Contrast this with ALS, with an economic burden amount-
ing to approximately $182 million.13 The discrepancy between what 
kills us and what costs us, and where we donate is a costly one, in 
terms of both dollars and lives.
Of course, the question must be raised: if we divert funding 
to the most lethal and burdensome diseases, what becomes of the 
rare diseases like ALS? Research and treatment for rare diseases re-
mains incredibly important, and funding is scarce by comparison 
to the major destinations of Canada’s health research funds. The 
top disease groups funded by Canada’s health research funding 
agency, the Canadian Institutes of Health Research, are cancer, di-
abetes, cardiovascular disease, and respiratory health, representing 
the major disease burden in Canada.14 This means that rare diseases 
like ALS need to be funded almost exclusively by charitable con-
tributions. In fact, ALS Canada has successfully raised substantial 
amounts of money towards research. In 2013, over $3.8 million was 
raised to support ALS research—a modest sum compared to the 
~$16.2 million raised by the Ice Bucket Challenge alone—however, 
one that is more in keeping with the proportional impact of ALS on 
the population.15 
conclusions
If we, as a society in Canada, wish to maximize the utility of 
our charitable donations, we might aim to be better informed as to 
what health problems are most pervasive and costly. The greater 
good of society should factor into decisions about where to direct 
charitable donations instead of relying solely on emotional or social 
motivations. Addressing this requires appropriate and balanced ed-
ucation. The recent ALS Ice Bucket Challenge phenomenon served 
as a great success for the fight against ALS, raising both money and 
awareness of the disease. However, it may represent a setback in the 
fight of society at large against the modern, chronic burden of dis-
ease. The goal is not to eliminate all funding for ALS, but rather to 
fund all diseases in proportion to their prevalence, economic cost, 
and mortality. A broad-minded society would attempt to erase the 
discrepancy between the diseases that kill us and cost us, and those 
which garner our attention. The final decision however, rests firmly 
in the hands of the donors.
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history of medicine
“In a hospital, the body is divided into departments. One de-partment for the ear, nose and throat, one for the eyes, one for the stomach and the intestines, one for the sexual organs, one for heart and blood vessels, and one for the soul, which is treated in the psy-chiatric wards. — Karl Ove Knausgaård, The Other Side of the FaceAs medical students trained with a mind for science, it is some-
times difficult to consider the human body as anything other than 
a series of anatomical parts. It is as if the human body is a great, 
complex machine that begins ticking early in the life of the embryo, 
and continues its autonomous functioning until the end, when sys-
tem by system, the machine will slowly dissemble and finally lay 
itself to rest.  The comparison of the human body to machine is 
called mechanization, and it is something that people have been do-
ing since the 17th century, the mechanical century. Thinking of this 
kind is closely linked to materialism—a philosophy that attributes 
all phenomena, including mental phenomena and consciousness, to 
be the result of material interactions—and largely informs the way 
we understand the brain and mind today. When materialism influ-
enced the understanding of the brain and mind during the 17th cen-
tury however, it posed a problem for Descartes, who was trying to 
accord the presence of a consciousness with the theological princi-
ples of the time. Cartesian mind-body dualism considered thought 
processes to be distinct from the body-machine, and it ascribed the 
thinking properties of the mind to an immortal and immaterial soul. 
The brain, specifically the pineal gland, was the seat of the soul. The 
soul was an individual’s connection to the heavens, and therefore 
not reduced to the materiality of the body.1 
While the consideration of the soul with respect to the brain 
and mind may seem strange to the scientific-minded medical stu-
dent, it is not an alien concept in medicine. Consider the two spe-
cialties that deal primarily in the brain and mind, neurology and 
psychiatry. Materialism is recognizable in neurology: a neurologist 
locates aberrant anatomical lesions throughout the nervous system 
and is generally able to explain neurological disease on the basis 
of objective findings and sound physiological reasoning. Mental ill-
nesses, on the other hand, are quite unique in that they are almost 
exclusively characterized by subjective symptomatology and rarely 
on discrete or objective findings. At the same time, we recognize to-
day that mental disorders can manifest with bodily symptoms. Not 
unlike Cartesian dualism then, mental illnesses have required the 
framework of a conceptual separation of mind and body. Descartes’ 
“soul” may not have disappeared from our mode of thinking after 
all, but instead, as Francis Azouvi suggests in an essay titled “Phy-
sique and Moral,” the concept of the soul may have simply been re-
placed by the psychological.1 
The division between brain and mind had not always been so 
apparent in medicine. It was not until the 19th century that med-
icine of the brain and mind truly diverged into the two separate 
specialties of neurology and psychiatry. As neuroanatomists were 
able to locate lesions related to specific diseases, the explanation 
for neurological illnesses became increasingly anatomical; likewise, 
the understanding of germ theory and use of microscopy enabled 
infectious disorders of the mind, such as neurosyphilis, to be under-
stood and treated definitively. Yet, psychiatric illness that could not 
be placed in the anatomical or physiological realm remained, and 
the understanding of the etiology of those mental illnesses was still 
heavily influenced by the tremendous optimism for materialism 
at the time.2 It is not surprising then, that the various treatments 
offered at asylums were somatic in nature—aimed at correcting a 
flawed nervous system using methods such as hydrotherapy, elec-
trical stimulation, and rest.3 But in the late 19th century to early 
20th century, the understanding and treatment of mental disorders 
would begin to look to the soul, or as it would come to be known, 
the psychological.  
Psychoanalysis has probably been most famed and subsequent-
ly defamed by the work of Sigmund Freud, although several other 
prominent neurologists, psychologists, and psychiatrists have made 
major contributions to the psychoanalytic movement and its re-
sultant schools of thought. In the absence of disease-specific brain 
abnormalities, proponents of psychoanalysis recognized that some 
illnesses appeared to have no discernable organic basis, and theo-
rized that psychological causes originating in childhood experienc-
es and the unconscious were the root of mental disease. Treatment 
was thus focused on techniques such as dream interpretation, free 
association, or transference, which did not aim to alter a physical 
aberration related to mental disease, but rather to subjectively ex-
plore the mind. The immaterial nature of a patient’s “psychology”, 
therefore, was investigated and manipulated in order to diagnose, 
treat, and sometimes cure mental disorders. 
At the turn of the 20th century, the connection between the 
body and mind in the history of medicine was not well defined. Both 
brain and mind had been implicated as the cause for mental and 
somatic disorders, and manipulating both the body and the mind 
had been considered as treatment regimens. Today, it is clear that a 
more modern understanding of the brain and mind incorporates a 
Separation and reunion
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unity between the two; thus over the course of the 20th century, we 
would come to see the divergent relationship of the brain and mind 
converging once again in medicine. 
The union of the structural and abstract theories of the brain 
and mind began in the late 19th century, but did not come to popu-
lar attention until the 1930s.4 In 1935, the first frontal lobotomy was 
performed in Lisbon, Portugal by Egas Moniz, a professor of neu-
rology, and Almeida Lima, a surgeon. The principle of the surgery 
was based on research that showed the association of the frontal 
lobes of the brain with temperament and behavioural control. Pro-
ponents of lobotomy surgery believed that dysfunctional behaviour 
was caused by pathological material located in the frontal lobes. Ab-
lating the pathological tracts of the frontal lobe was the goal of the 
therapy. The side effects from the procedures performed were nu-
merous: while some patients became more docile after the opera-
tion, others experienced an increase in impulsive behaviour, lack of 
initiative, and reduced ability to think or plan clearly. Effectiveness 
of the procedure was strongly debated, and it was popularized by 
the media as one of the greatest medical blunders of the time; how-
ever, though infamous, frontal lobotomy has contributed greatly to 
the study of mind and behaviour, particularly by demonstrating the 
role of neuroanatomy in human psychology.5 
Three years after the first lobotomy surgery was performed 
in Portugal, two Italian physicians, Lucio Bini and Ugo Cerletti, 
completed the first session of electroconvulsive therapy (ECT) on 
a catatonic patient. This initial use of ECT relied on the under-
standing that electrical stimuli could be used to induce seizures in 
order to treat psychiatric abnormalities. The 1938 treatment was 
a success, and even though the exact mechanism remains elusive, 
ECT is used today for treatment of major depressive disorders in 
select patients.6 The use of ECT was closely followed by treatments 
established in psychopharmacology. The introduction of psycho-
pharmacology began in the early 1950s, with the first wave of psy-
chotropic medications providing a treatment option for previously 
untreatable psychiatric conditions.7 The therapies were based on 
an understanding that neurochemical imbalances in the brain can 
precipitate psychological disorders, and offered yet another physio-
logical mode of viewing the interaction between brain function and 
mental phenomena. 
Today, it is recognized that a combination of psychotherapy, 
medical therapy, and even surgical therapy can be effective in treat-
ing mental illnesses.8 But unlike a pathogen being eradicated by an 
antibiotic, or a structural defect being corrected, individual patient 
responses to psychiatric treatments are unique; that is, those that 
respond to some therapies may not respond to others, and the re-
sponse cannot always reliably be predicted. In light of these endur-
ing limitations of modern medicine, it causes one to question how 
far we have come from the lobotomy surgeons of the past. 
The scientific investigation of the brain and mind has made 
great strides over the past century in order to advance the study of 
mental disorders. Improvements in surgical techniques and imag-
ing modalities will only act to further advance the understanding of 
the brain and mind. The trouble of course is that there is still much 
to understand before we can arrive at a complete understanding of 
mental disorders. The Diagnostic and Statistical Manual of Mental 
Disorders (DSM) is just one example of how psychiatric medicine 
is still largely reliant on subjective symptomatology. Despite the 
impressive research in functional neuroanatomy and neurobiology 
being undertaken, there still does not exist a laboratory test, or di-
agnostic imaging that can reliably identify psychiatric illness. This 
may be because the brain and mind is one of the most complicated 
areas of medicine that humans have attempted to understand. No 
other anatomical structure contains such a vast amount of informa-
tion transmission to decode. If one considers that the knowledge 
we currently have may represent only the tip of the iceberg, the fact 
that many of the treatment regimens we use today work for patients 
can seem miraculous. So if the discovery of how the mind works is 
still ahead of us, we must somehow create a model of the brain and 
mind that does not rely on the purely physical or the purely psycho-
logical. It seems that despite our vast increase in knowledge since 
the time of Descartes, not much has changed in the fundamental 
theory of body and soul. 
In A Scandalously Short Introduction to the History of Medi-
cine, Jaclyn Duffin warns us that the over-mechanization of the 19th 
century risked the loss of insight into the mind-body connection.2 
But increasingly the culture of medicine has been reaching back to 
incorporate the subjective patient experience to include a spiritu-
al, cultural, and psychological understanding of illness. In the 21st 
century, perhaps a rigorous pursuit of knowledge will not cause us 
to lose sight of the mind-body connection, but instead, enlighten us 
with a greater appreciation for the body and the soul. This happy 
marriage of objective science and subjective patient experiences 
may be the aspect of modern medicine that allows for a deeper un-
derstanding of the mind-body connection, and ultimately, creates a 
culture of medicine that reserves a space for the soul.
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case presentation
The patient was only 6 years old but he had already been to 
the hospital almost a dozen times. Today, as he was led to the 
examination room, he clung tightly to his mother’s side. When 
asked to take a seat in the examination chair, he began to cry. 
Although he had been to the hospital more often than most kids 
his age, he clearly didn’t find the setting enjoyable and he didn’t 
want to be separated from his mother.
The patient had mild exotropia (outward deviation of the 
eyes) from an early age. While he had never explicitly complained 
of vision problems, he had a history of squinting frequently and 
turning his head in an attempt to see more clearly. His mother, 
on several occasions, had further suspected him of “seeing dou-
ble”. On examination, the patient was diagnosed with amblyopia 
and strabismus, and placed under the care of Charla, an orthop-
tist at St. Joseph’s Hospital, London.
On this occasion, the patient was very distraught by being in 
the examination room. Charla was reluctant to have him take a 
seat because he obviously wanted to be with his mother. Luckily, 
Charla had a number of toys she kept in the office that she was 
able to take out and have the patient play with to distract him. 
The clinical exam comprised of a cover test for type of ocu-
lar deviation, horizontal and vertical prism bars to measure the 
size of strabismus, Worth’s four light test for assessing degree 
of binocular vision and suppression and having the patient go 
through an image book and choose the image that looked “3D” in 
order to assess binocular vision. 
Over the course of the 30-minute appointment, a drastic 
change overcame the demeanor of the patient. He had trans-
formed from being quite distressed to more comfortable and 
actually seemed to enjoy the various “games” that made up 
his exam. The patient and his parents left the office with in-
structions to patch the unaffected eye in order to strengthen 
the muscles in the weaker eye and restore proper vision and 
alignment. 
discussion
The 6-year-old boy with amblyopia and strabismus was one of 
many patients I saw with an orthoptist during an observership in 
the ophthalmology clinic at St. Joseph’s Hospital. Prior to my ob-
servership, I had never even heard of the profession. Luckily, I got 
to spend the day with Charla Snow, a practicing orthoptist at St. 
Joseph’s. 
Orthoptists are allied health professionals who specialize in 
the study of eye movements, eye alignment and binocular vision.1 
Orthoptists work closely with ophthalmologists in managing dis-
orders such as amblyopia and strabismus. While ophthalmologists 
formulate and implement surgical interventions, orthoptists pro-
vide primary care in the assessment, diagnosis and non-surgical 
treatment of optical complaints.1 
Strabismus is a condition in which the eyes are not properly 
aligned. It is caused by an inherently misaligned eye or by a lack of 
coordination between the extraocular muscles, preventing the eyes 
from being able to focus on the same point in space.2 Symptoms in-
clude diplopia, eyestrain and loss of depth perception.2 In young 
patients such as the 6-year-old from the case presentation, stra-
bismus is particularly worrisome because of the risk of developing 
amblyopia, a condition in which the brain compensates for the lack 
of ocular alignment by suppressing vision in one eye.3 The result 
is a form of cortical blindness where connections between the eye 
and the brain do not develop properly and the brain consequently 
ignores the images coming from that eye.3 In the management of 
strabismus and amblyopia, orthoptists use a combination of glasses, 
occlusion (patching) and prism therapy.1 Orthoptists also monitor 
and reinforce the treatment plan by meeting with the patients on a 
regular basis and offer support and guidance to the patient and his 
or her family.1
Orthoptists work with a patient population that ranges from 
infants just a few months old to seniors, but the majority of their 
practice deals with children. As such, orthoptists have special skills 
that facilitate working with this age range.1 In general, children 
have shorter attention spans and are more difficult to examine than 
adults.4 As such, orthoptists use a variety of tests designed to work 
within the brief window of a child’s attention span. For example, in 
order to check extraocular eye movements, Charla would have the 
children track a toy with their eyes. The tests are also customized 
for various age groups: the younger children were given the sim-
pler task of naming shapes, while the older children were given the 
more complex task of naming letters.
During my day at the clinic, I learned that orthoptics training 
is at least two years in length following an undergraduate degree, 
and often includes a third thesis year for the completion of a mas-
ter’s degree.5 The curriculum involves learning the unique anatomy, 
physiology and clinical skills required to excel in such a specialized 
career. Just like medical schools, orthoptics programs in Canada 
are accredited by the Canadian Medical Association and all train-
ees must write a 3-part national examination set by the Canadian 
Orthoptic Council.5
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When we had a break between patients, I asked Charla where 
orthoptists fit into the larger scheme amongst optometrists, oph-
thalmologists and general practitioners. I was told that her practice 
has a very specialized scope of practice and orthoptists are able to 
specialize in studying ocular motility and visual development.1 Al-
though orthoptists cannot perform surgeries and require an oph-
thalmologist to work with them, having an orthoptist involved in 
patient care means the management and treatment can be moni-
tored more closely, enhancing the quality of patient care and overall 
sense of patient satisfaction.6,7
conclusion
Towards the end of the day, I asked whether Charla ever ran 
into conflicts with other members of the ophthalmology team. She 
told me that having the ophthalmology clinic centralized at one hos-
pital makes them a tight-knit group and contributes towards a high 
level of interprofessional collegiality. Although there are occasion-
ally differing opinions on the final diagnosis or different thoughts 
about how a patient should be managed, Charla emphasized the 
importance of trusting the skills that each specialty brings to the 
table. Spending the day in clinic with Charla really brought home 
to me that, regardless of what medical specialty I end up choosing, 
developing a trusting and respectful relationship with allied health 
professionals and working together effectively would be critical to 
providing the best patient care possible.
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abstract
The nature of the brain presents many challenges to its 
study, from the intricacy of its structure to the minute times-
cale at which it functions. Traditional research techniques, 
such as electrophysiological manipulation and pharmacologic 
intervention, are limited by their inability to operate with both 
high temporal and spatial resolution. Optogenetics is a novel 
technology that provides unparalleled specificity in this re-
gard. It allows for control of neural activity with high temporo-
spatial resolution in a manner that does not disrupt the normal 
physiology of the system. It is an elegant research tool that uses 
light to control the electrical activity of genetically defined 
neuron populations with millisecond precision in systems as 
complex as freely moving live animals. First demonstrated in 
2005, it was identified by Nature as the Scientific Method of the 
Year in 2010 and is currently used by thousands of labs across 
the world. It has already yielded new discoveries in a variety 
of neuroscience subfields and will undoubtedly continue to do 
so. The technology currently exists in a basic science capacity, 
but has potential for therapeutic application. It is not without 
its own limitations, but has advantages over more crude alter-
natives and has proven to be a powerful tool in the hand of the 
neuroscientist.
introduction
The human brain is the most intricate organ in the body and 
has been referred to as “the most complex object in the known uni-
verse.”1 A recent estimate put the number of neurons in the human 
brain at 86 billion2 with each neuron forming hundreds, if not thou-
sands, of individual connections through which they communicate 
on the millisecond scale. The complexity of its structure and func-
tion is astounding. For neuroscientists, this makes the brain both 
irresistibly fascinating and prohibitively difficult to study. In order 
to overcome the challenges that result from the inherent complexi-
ty of the brain, investigators must be creative and innovative in their 
approach to its examination. The recent development of a research 
tool known as optogenetics provides an ideal example of such in-
novation.
background
Traditional methods of study, such as with electrophysiologi-
cal devices or pharmacologic intervention, have provided countless 
insights into how the brain operates. However, each technique has 
limitations. Direct electrical stimulation of tissue has high temporal 
resolution, but indiscriminately affects all cells around the micro-
electrode and thus has poor spatial resolution.3–5 Given that specif-
ically targeted neurons are often sparsely embedded within tissue, 
this is a significant drawback. Pharmacologic intervention on the 
other hand has high spatial resolution, as drugs can be designed to 
act on only certain neuron populations, but because the drug can 
stay in the system for anywhere from minutes to hours such an ap-
proach lacks temporal resolution.4,5 Given the minute timescale at 
which the brain operates, this is also a significant hindrance.
The idea of using light as a medium to control the activity of 
neurons is not novel. It was speculated on by Francis Crick as far 
back as 1979,6 however it was only first demonstrated in 2005.7,8 
Since then, the lab of Karl Deisseroth at Stanford University has 
published extensively on the topic9–17 and optogenetics has spread 
to thousands of labs across the world.18 It is an elegant technique 
that uses light to control the activity of genetically engineered neu-
rons and has significant advantages over its more crude alterna-
tives. Its significance has been recognized throughout the scientific 
world, notably with Nature naming it Scientific Method of the Year 
in 2010 and its early developers being honored as recipients of The 
Brain Prize by the Grete Lundbeck European Brain Research Foun-
dation in 2013.
details
Optogenetics, quite literally, refers to the convergence of optics 
and genetics. When applied to neuroscience, it is a technology that 
uses light to control the electrical activity of neurons with both high 
temporal and spatial resolution in a manner that minimally disrupts 
the normal physiology of the system. Thus, it overcomes some of 
the limitations associated with traditional research techniques as 
described above.
In order to achieve this, single-component, microbial-derived, 
light-activated ion channel proteins called opsins are artificially 
expressed in the membranes of neurons. This is predominantly ac-
complished through the use of viral vectors carrying specially de-
signed genetic constructs, but can also be achieved using transgenic 
animals.19 Regional specificity when using viral vectors can be en-
sured via the use of specific promoters, by localized viral injection, 
and by restriction of opsin activity via targeted light delivery.4,20 The 
family of proteins in play, opsins, was first discovered as a compo-
nent of bacterial cell membranes over 40 years ago.21 Since then, 
further research has enlarged the family and proteins have even 
been altered in the laboratory to be more suitable for optogenet-
ics research purposes.22 There currently exist dozens of opsin types 
with unique characteristics, thus allowing for a variety of experi-
mental configurations.22
Optogenetics
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The genetic engineering techniques employed ensure that 
the opsins are expressed exclusively in genetically defined target 
population(s) of neurons and thus provide spatial resolution to the 
cell-type level.23 Light is delivered via surgically implanted fiber 
optics9–11 or other means.7,20,24 Upon exposure, the opsins alter their 
conformation such that the flow of ions in or out of the neuron of 
which they are a part is altered.22 Depending on both the type of 
opsin involved and the wavelength of light used, the target cell(s) 
are either depolarized (excited) or hyperpolarized (inhibited).22 
This use of light as the metaphorical on/off switch for neuron ac-
tivity provides the high temporal resolution. The light source can 
be pulsed with enough speed and precision so as to reliably elicit 
single spikes in neuron electrical activity.8 Furthermore, light is an 
ideal medium to use for this purpose as it does not affect unaltered 
neurons (neurons without opsins) and thus minimally disrupts nor-
mal brain physiology.8
recent research
Before discussing relevant current research, it is important to 
note that optogenetics currently plays a role in basic science re-
search exclusively. That is, its goal is not directly therapeutic, but 
to give neuroscientists the ability to more closely examine the brain 
and thus better understand how it functions. It is used in models of 
both health and disease with the hope that the knowledge gained 
will lead to the development of future therapies.
Optogenetics has been applied to nearly every area of neuro-
science research18 and in models ranging from ex vivo cell lines8 
to nonhuman primates.20 A sample of notable work using murine 
models includes controlling behavior in freely moving animals,15 
increasing functional recovery after stroke,10 mapping of Parkinso-
nian neural circuitry,12 inhibiting symptoms in a model of Parkin-
son’s,11 eliminating cocaine seeking behavior after addiction,16,25 and 
inducing REM sleep.26 Last year researchers used optogenetics to 
control in vivo transcription of endogenous genes in the brain, as 
opposed to electrical neural activity.27
These represent some of the most dramatic recent advances in 
optogenetics, but there are countless examples of labs applying this 
technology to less complex in vitro systems. In vitro application of 
optogenetics, such as in vitro slice electrophysiology, benefits from 
the same principles that allow for exciting research in in vivo mod-
els, but is significantly less expensive (a few thousand dollars will 
provide for a good start).28
future directions
Although optogenetics has come a long way since its debut a 
decade ago, it remains in its infancy. There is enormous ongoing 
research into its refinement and further development with excit-
ing papers being published almost monthly.29 One intriguing topic 
is the development of optical systems capable of the simultaneous 
control and recording of neural activity. This is not possible to per-
form with electrophysiological devices and is just beginning to be 
performed using optogenetic systems. It would provide unprece-
dented information about the organization and function of intact 
neural networks.18,20,23
The use of optogenetics as therapy for human disease is a nat-
ural direction to look in when considering the future of this tech-
nology. This, for reasons discussed below, is a distant, but not im-
possible, prospect. Based on current research, it could be applied in 
various forms to assist in treating disease states including Parkin-
son’s,11,12 addiction,16,25 stroke recovery,10 epilepsy,17,30 and a variety of 
neuropsychiatric diseases.4,31,32
limitations
As with any new technology, the limitations of optogenetics are 
slowly appearing. Relating to basic science use, the pattern of ion 
concentration changes induced by opsins does not perfectly rep-
licate the actions potentials observed in normal physiology.29 The 
conductance tends to be smaller33 and the magnitude of the ion con-
centration changes risks exceeding physiologic ranges.18 Exposure 
of multiple opsin-containing neurons to light means their resulting 
activity is synchronized and, given the precise timing of neural net-
works, potentially results in nonphysiologic patterns of activity.18 
Furthermore, although light has desirable properties the heat creat-
ed by its use poses a significant risk of damaging delicate tissue and 
is something researchers must be cognizant of.28 These limitations, 
among many others, threaten the validity of conclusions drawn 
solely from the interpretation of optogenetic results.
Besides the onerous task of compiling the knowledge of neu-
ral function and dysfunction required to even hypothesize about 
the use of optogenetics in the treatment of human disease, a major 
limitation to this application is the dependence on genetic manip-
ulation. Proving the long-term safety of gene therapy in humans to 
the satisfaction of regulatory bodies is an immense undertaking.18,34 
Combined with additional objectives, such as refining the methods 
of light delivery in intact living tissue and demonstrating therapeu-
tic effects beyond the scope of other methods, an enormous deal of 
work needs to be completed before therapeutic application of opto-
genetics can be considered.5
summary
Optogenetics is a novel and sophisticated research tool. 
Through the convergence of genetics, optics, and neurobiology it 
allows for the control of neural activity with unparalleled tempo-
rospatial resolution in systems as complex as freely moving live an-
imals. It is an elegant technique with significant advantages over 
more crude alternatives and has provided us with new insights into 
how the brain functions. With continued application and refine-
ment it will continue to do so. It is currently applied only in terms 
of basic science research, but has potential for a therapeutic role in 
a variety of diseases.
Given its intriguing core principle (controlling the brain with 
light), optogenetics is a topic prone to sensationalization and one 
needs to keep in mind that significant limitations exist at both the 
basic science and potential therapeutic levels.
In closing, I paraphrase the cautious champion of optogenet-
ics, Karl Deisseroth, who said that optogenetics, although exciting, 
should be viewed as only one tool among the many available to a 
neuroscientist.32 Nevertheless, considering the task at hand, it is 
one that I would want in my kit.
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In the first of three interviews in this issue, we speak to 
Dr Javeed Sukhera. Dr Sukhera is an Assistant Professor in the 
Department of Psychiatry and Senior Designate Physician Lead 
for Child and Adolescent Psychiatry at London Health Sciences 
Centre/Victoria Hospital. He is also the Academic Director of the 
Global Health Curriculum at Schulich. Dr Sukhera has previously 
served for two years on the board of directors of the Association of 
American Medical Colleges.
UWOMJ: Tell us about yourself, specifically your education and 
career.  
Javeed Sukhera: I am originally from Toronto and did my un-
dergraduate training there. I took the opportunity to study medicine 
in Israel, which is where I was able to further explore my interests 
in global health. I studied at the Medical School for International 
Health, an innovative collaboration between Columbia University 
and Ben-Gurion University in Israel. During my fourth year, I re-
turned to Canada for an elective in adolescent psychiatry and that 
is what sparked my interest in psychiatry. Prior to the elective, I was 
was close to pursuing family medicine, but inevitably chose psychi-
atry. I then completed my residency in Rochester, New York, as well 
as my fellowship. Two years ago, I decided to return to Canada, and 
I came to London, Ontario. 
What made you interested in pediatric psychiatry? What makes 
this field unique?
I think that psychiatry is very unique because it is so different 
from every other field in medicine. All throughout medical school, 
you are taught to think a certain way. In psychiatry, you have to un-
learn the need to always try to find a solution or a cure. There is 
not always a medication or a quick fix within psychiatry, and often, 
there is the opportunity for different methods of patient manage-
ment. Pediatric psychiatry is especially interesting because you are 
working with a population during a developmentally sensitive peri-
od that can have a long-lasting impact on the patient’s life. 
Tell us about your other academic or personal interests and how 
you balance that.
Between clinic, research and academic teaching responsibili-
ties, I would roughly estimate that 40 percent of my time is clini-
cal, 40 academic and 20 research. I was recently awarded a grant to 
conduct research on unconscious biases within medicine and how 
they affect patient outcomes. Due to my appointment, I also have 
several academic responsibilities. For example, I am the Academic 
Director of Global Health Curriculum at Schulich. At the Office of 
Global Health, we have worked hard to integrate global health and 
public health topics into all four years of the undergraduate cur-
riculum. Specific examples include the cultural competence work-
shop in your Population Health course and a Health Equity Panel in 
the Healthcare Systems course. 
Global health is something that is very important to me and is 
an important part of my career. The old version of global health in-
volved going abroad and providing healthcare in countries outside 
of Canada. Over time, we have recognized the problem of medi-
cal tourism, but also recognize that there is a benefit to learning 
medicine in different cultural environments. More recently, global 
health is more about the patients sitting in front of us, especially in 
Canada, and how understanding local and global contexts helps us 
understand the social and cultural determinants affecting this spe-
cific patient’s care. Many students struggle with the idea of global 
health in a local setting, but the same principles relating to cultural 
competency apply both locally and globally.
How would you compare psychiatry to neurology or neurosur-
gery? What are the similarities or differences that you see? Do 
you often work in interdisciplinary teams? 
I would say that neurology is somewhere between psychiatry 
and neurosurgery. We definitely work with neurology on certain 
cases. The problems that we see are often biosocial in nature, and 
there are referrals that flow in both directions. I would think of 
neurology as a field that deals with the brain whereas psychiatry 
is a field that deals with the mind. It is on rare occasions that we 
might work with the neurosurgeons. More often than not, we might 
be consulted by neurosurgery. The main difference for psychiatry 
that makes it unique from other specialties is that psychiatric com-
plaints are multifaceted and very complex. Just this morning, I saw 
a boy with attention deficit hyperactivity disorder (ADHD)—a very 
bright boy. Early on, he had acknowledged how he might have been 
different and he has done well working with me. Our conversation 
was not limited to his medication, but also the social aspects of his 
illness. When someone has ADHD, it affects many parts of his life, 
such as his education and friends, just as some examples. My treat-
ment extended beyond offering medication and included providing 
the opportunity to openly speak about the challenges of being a 
teenager who may need to rely on medication while trying to fit in 
with his peers. 
Tell us about your family, or hobbies you have outside of work. 
I am very lucky to have two beautiful children with my wife. 
We all enjoy travelling, but my favourite hobby would probably be 
just doing nothing on a Sunday afternoon. 
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Do you have a memorable case to share?
There are just so many cases that are memorable. This one case 
that I remember is actually from when I was a fourth-year medical 
student. The patient was an adolescent male who adhered to Or-
thodox Jewish practices. He had very specific requests for his psy-
chiatric care. For example, he refused to be touched by the female 
nurse. At the time, my supervisor was actually also a rabbi, and he 
was able to communicate genuinely with the patient. His approach 
showed a lot of patience and understanding. In the end, the solution 
that was finally agreed upon was for the patient to receive care from 
the nurse, who would be able to touch him with gloves on. 
What do you see as the challenges/innovations within psychia-
try in the next 20 years?
I think a current challenge is the bias within medicine that a 
lot of my patients face. You would be surprised at some of the com-
ments that I hear from other physicians that stigmatize patients 
with psychiatric illness. The treatment that a lot of psychiatric pa-
tients receive is simply unfair and stems from ignorance. Especially 
in emergency rooms, these patients often face a lot of discrimina-
tion. 
With psychiatry, there is also a great need to advocate for my 
patients. There are essential and vital medications or treatments 
that are not available everywhere. For example, some of my patients 
from more rural locations do not have access to a psychiatrist near 
them. Can you imagine that for other illnesses? For a diabetic not to 
have access to insulin or a heart failure patient to not be able to be 
pay for ACE inhibitors? It would be unheard of! Within psychiatry, 
there is a lot more for us to advocate for. This is a real challenge that 
I unfortunately see in my practice. Moving forward, there is a lot of 
room for improvement. 
I see a lot of changes upcoming in psychiatry, especially with 
new psychotherapies, and psychopharmacological treatments that 
are being researched. So, there are some positive things to look for-
ward to as well.  
What are your thoughts about the new Diagnostic and Statistical 
Manual of Mental Disorders (DSM) V? 
I am not a huge fan of the DSMs because I find that their cate-
gorizations oversimplify the problems that we are presented with. 
The DSM is helpful for providing guidelines for diagnosis, but most 
of our patients do not fit neatly into the categories that the DSM 
provides. I prefer to address the person in front of me instead of 
treating a formulaic diagnosis provided by the DSM. 
If a medical student is interested in psychiatry, do you have any 
advice for them?
I would just say that there are many different facets to psychi-
atry. Pediatric psychiatry, for example, is very different. There is a 
lot to experience and see in psychiatry. Use the clerkship psychiatry 
rotation to explore and be open minded. You may be surprised at 
what interests you and what field you can imagine yourself prac-
ticing in.
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In the second of three interviews in this issue, we speak to 
Dr Christen Shoesmith. Dr Shoesmith is a neurologist and the di-
rector of the Motor Neuron Diseases Clinic at the London Health 
Sciences Centre (LHSC). She runs the local clinical research trials 
in amyotrophic lateral sclerosis (ALS) and also sits on the ALS Can-
ada Scientific Medical Advisory Panel. She is also heavily involved 
in medical education at the undergraduate, residency, and fellow-
ship levels. She is an Assistant Professor of Neurology at Western 
University.
UWOMJ: Tell us a bit about yourself, specifically your educa-
tion, career, and personal interests.
Christen Shoesmith: After studying medicine at the Universi-
ty of Manitoba, I completed my neurology residency and fellowship 
here in London. I was fortunate enough to stay on staff after fellow-
ship and have been a staff neurologist at LHSC since 2007. 
I subspecialize in ALS and am the clinical director at the Motor 
Neuron Diseases clinic at University Hospital. I also have a partic-
ular interest in patients who have neurological symptoms during 
pregnancy. 
Aside from my career, I love spending time with my husband 
and my two beautiful daughters who are 7 and 5 years old, and I 
enjoy jogging and yoga.
Why did you choose neurology? 
I came into medical school with an interest in neurology, but 
was open to other potential specialties, which I explored through 
observerships. My undergraduate degree was in chemistry and 
mathematics, so the analytical and algorithmic approaches to neu-
rological problems were very stimulating for me. I also loved the 
diverse patient population and the thrill of the diagnosis. In neu-
rology, we see patients in their 20s through their 90s with a variety 
of neurological disorders. In my first two years of medical school, I 
attended weekly neurology teaching rounds at the adjoining hospi-
tal, and had great mentors who helped me grow in my knowledge 
and exposure to neurology in medical school. 
When I started my neurology residency here at Western, I 
loved everything about the field, but it became clear early on that 
I had an interest in palliative care. Initially I explored neuro-on-
cology but I didn’t feel it involved sufficient intellectual challenge 
for me, since the diagnosis is already there when the patient comes 
into your care. In contrast, working in the field of neuromuscular 
disease and ALS gave me the thrill of localization and diagnosis, 
so it was a natural fit. I also had the complete fortune of having 
Dr Michael Strong as my mentor in my residency and fellowship. He 
was instrumental in guiding me through my early career opportunities.
Thoughts on ALS ice bucket challenge?
In the ALS community, everyone is absolutely thrilled that the 
ice bucket challenge happened. Patients spread awareness about the 
disease they’re living with, and the community has a much broader 
understanding of how ALS can affect individuals and families.
Some people in the lay media have spoken out against the ice 
bucket challenge saying that the funds should have been divided 
more equitably amongst other diseases initiatives. However, ALS 
rarely has its face in the spotlight or gets large sums of funding, un-
like cancer or heart and stroke. 
The other negative publicity issue is that people have looked at 
the financial statements of ALS Canada and assumed that the dis-
tribution of the new funds would be made in the same percentages 
as previously. However the cost of running the organization won’t 
change substantially, so this one-time donation can be diverted di-
rectly to patient support services and research.
Is there a memorable case you would like to share?
The cases that I remember most are the ones where I have 
made the right diagnosis that other clinicians may have missed. It is 
rewarding to know that you’ve spent the time and energy to make a 
correct diagnosis. The cases where I have made mistakes or where 
I did not use the best clinical judgment are also memorable, as well 
as those cases with complex ethical issues. Some patients have dis-
placed their anger on me about their diagnosis of ALS. I’ve learned 
to appreciate that patients have different reactions to diagnoses, 
and a negative reaction doesn’t necessarily mean that you’ve pro-
vided bad care to the patient.
What can you do as a neurologist to make sure that you catch the 
diagnoses others have missed?
It is very important in neurology to take a great history: let the 
patient tell their story and not put words into their mouth. Listening 
to all facets of the story is really important so you can hear about the 
progression of their symptoms over time. Next, unlike a lot of other 
areas of medicine, a meticulous physical examination in neurology 
is still extremely important and it is vital to arriving at a correct di-
agnosis. To put together a diagnosis, it’s important to take the time 
to think about what all the findings mean. You also can’t be afraid to 
revisit a diagnosis, whether it is your own or someone else’s. 
The field of neurology is still perceived by many to be a field of 
diagnosis rather than curing. What are your thoughts on this is-
sue?
From an outsider’s perspective, there is the perception that 
neurology is a “diagnose and adios” profession. But neurology has 
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absolutely changed—it’s a very different field than when I was a 
medical student. When I started as a medical student, there were 
very few treatments available for multiple sclerosis (MS). Now, 
we’ve got multiple drugs that have substantially improved the 
course of MS. Inflammatory conditions, stroke, epilepsy, and sei-
zures have also seen tremendous improvements in management. 
There are, of course, neurologic disorders that we can’t treat 
yet, but there are huge amounts of research being done and I cer-
tainly think that in my lifetime, diseases like ALS will have better 
treatments. I never tell my patients we can’t do anything about their 
diagnosis. I explain that we can help manage symptoms with phar-
macological management and we also direct people to appropriate 
allied health professionals. For example, getting an ankle foot or-
thotic for someone that has foot drop, or getting the appropriate 
therapist to help with dysphagia can make a huge difference in a 
patient’s quality of life. 
How much do you interact with neurosurgeons or psychiatrists? 
In London we have a Clinical Neurological Sciences depart-
ment, so neurosurgeons and neurologists are part of the same facul-
ty, sharing the same resources and physical space. At our site, there 
is likely more academic interaction between neurology and neuro-
surgery than at centres where the two specialties are under sepa-
rate departments (medicine and surgery). This model allows for a 
shared type of care where we can learn from each other.
Where do you see neurology going in the next 20 years or so?
There will be more treatments for genetic conditions in neu-
rology. A lot of research is being done but right now there aren’t 
specific treatments for most genetic disorders in neurology. As well, 
we’ll be moving more towards more personalized medicine where 
different genetic factors will predict different treatments for neu-
rological disorders. 
From a career perspective, what are the job options and oppor-
tunities for neurologists when they finish residency?
Unlike neurosurgery where underemployment is an issue, neu-
rology doesn’t have that problem. There are certainly many urban 
centres and smaller centres like Thunder Bay and Sudbury that are 
looking for more neurologists. The majority of the positions are not 
in academic institutions at the moment, but soon many neurolo-
gists will be retiring. As well, because the baby boomer population 
is getting older and neurological disorders are more prevalent with 
increasing age, there will be an increased need for neurologists over 
time.
If students are interested in neurology, what should they do to 
further explore the field?
For students who are interested in neurology, it’s worth getting 
perspectives from different types of practices and many neurolo-
gists through observerships and electives. Medical students can also 
attend Clinical Neurological Sciences grand rounds, as well as neu-
rology lunchtime rounds. The schedule for weekly rounds is avail-
able online on the Clinical Neurological Sciences website. Research 
is sometimes a bonus when applying for neurology residencies, but 
not necessary. From a preceptor’s point of view, the students that 
are eager to learn in a clinical setting and have a basic knowledge of 
neurology/neuroanatomy are the ones that are teachable and a good 
fit for the program. 
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In the third of three interviews in this issue, we speak to Dr 
Fawaz Siddiqi. Dr Siddiqi is an Assistant Professor of Neurosurgery 
and Orthopaedics at Western University. He is the president of the 
Professional Service Organization and sits on the Medical Advisory 
Committee as well as the London Health Sciences Centre Board of 
Directors. He is also the course chair for the Healthcare Systems 
course at the Schulich School of Medicine and Dentistry.
UWOMJ: Tell us a bit about yourself, your career path and your 
education path.
Fawaz Siddiqi: I did my undergraduate degree in biochemistry 
at the University of Ottawa and came to Western for medical school. 
I did my neurosurgery residency training and an orthopaedic spine 
fellowship here, after which I came on as faculty. Clinically, I’m one 
of four spine surgeons in our combined neurosurgery and ortho-
paedic spine program at Victoria Hospital in London. My practice 
encompasses degenerative spinal conditions, oncology, and trauma.
What made you interested in neurosurgery? What makes it 
unique?
My attraction to neurosurgery happened relatively early in my 
career. I spent my summers after first and second year of medical 
school with the neurosurgical service at a hospital back home in 
Ottawa. Spending time with the neurosurgical team helped me de-
termine whether it was something I wanted to do. 
Neurosurgery is a challenging field to work in and it attracts 
people who really crave that sort of challenge. The procedures and 
patient population are very diverse. Neurosurgeons perform many 
procedures to help people with a variety of conditions. Neurosur-
geons help with chronic pain through spinal cord stimulation, with 
movement disorders such as Parkinsonism through the use of deep 
brain stimulation, and curing epilepsy with surgical resections. In 
addition, we deal with oncological conditions of the brain and spine 
as well as vascular conditions, such as cerebral aneurysms and vas-
cular malformations.
Spinal surgery itself is very rewarding. Patients come in who 
have a lot of difficulty walking and they can walk again after the op-
eration. That’s not something that a lot of specialties can lay claim to.
How would you compare neurology, psychiatry, and neurosur-
gery? 
While the pathologies may overlap, the objectives and practice 
patterns of the practitioners are very different. That said, there is 
a huge amount of crossover between neurosurgery and neurology 
in terms of pain management, treatment for movement disorders, 
and epilepsy. Surgeons who work in those fields usually work in 
interdisciplinary teams. Epilepsy is a perfect example. You can’t 
be an effective epilepsy surgeon if you don’t have an effective epi-
lepsy neurology partner. The same is true with movement disorder 
work. The bulk of my collaboration with other physicians is with 
oncologists and neurologists. As for psychiatry, there are more and 
more data suggesting that stimulation of certain areas of the brain, 
namely the areas of the limbic system and the cingulate gyrus, can 
actually help with depression as well. 
Can you tell us a little bit about your Master of Business Admin-
istration (MBA) or other academic or personal interests you 
have?
During training, neurosurgical residents usually get a research/
elective period of about 9 months. Most people will use that to do 
a master’s degree of some sort or a research project or an elective. 
When I looked at the breadth of options available to me, the MBA 
seemed to be the most effective degree in looking at healthcare 
systems operationally and being able to work through some of the 
problems that we have such as delivery of care to our patients. 
For a physician who is involved in management, it can be a very 
powerful tool to have in your back pocket. I encourage people to 
look into it as a professional career option as the healthcare system 
evolves and encounters new difficulties, whether it be a funding 
perspective or from a structural perspective. We are going to need 
more and more physician voices involved in these issues.
One of the current projects that I am involved with at an insti-
tutional level is collaborating on working towards achieving better 
physician participation in healthcare management. Since the bulk 
of healthcare costs actually are driven by the physician’s pen, phy-
sicians need to be more engaged in healthcare institution manage-
ment in order to achieve efficient healthcare delivery. Traditionally, 
physicians worked as islands in most hospitals and clinics with very 
little oversight or participation in attempting to make the system 
better. This archaic model has to change.
What do you think the challenges are in neurosurgery in the next 
twenty years?
The outcomes from primary brain tumour treatment haven’t 
changed much in the last number of years, and the prognosis re-
mains pretty dismal for some types of brain tumours (12-14 months 
median survival with maximal therapy for primary high-grade gli-
oma). So, from a research and innovation perspective, the causative 
factors of primary brain tumours still remains elusive. 
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The other challenge is really delivery of care. The wait list for 
a spinal surgery can often times reach two years for consultation, 
and an additional year for surgery. The way we deliver consultative 
services to patients has to change. We can’t rely on the tradition-
al model where you have a physiotherapist, chiropractor, or family 
physician refer to a surgeon in isolation. We really need an interdis-
ciplinary model of care for this specific patient population that will 
shorten wait times and improve evidence-based care.
What’s new and exciting in your field of neurosurgery? 
We are achieving a much better understanding of spinal bio-
mechanics and becoming better at treating spinal diseases, wheth-
er minimally invasively or with open surgery. There is increasing 
awareness of the role of neurosurgery for epilepsy surgery, as well 
as for Parkinsonism, movement disorders, and chronic pain condi-
tions. 
Do you have any comments about future job prospects in neuro-
surgery in Canada and elsewhere?
We have not had enough jobs in Canada to sustain the number 
graduating from neurosurgery, so many neurosurgeons found jobs 
in the United States after training. Most centres in the US are still 
hiring Canadian-trained neurosurgeons and recognizing the Cana-
dian training. In my year, we had three of us stay in Canada and 
everyone else went to the US, and as far as I know, everyone is em-
ployed and has fantastic jobs. 
Are there opportunities for working abroad for medical relief 
purposes?
Organizations tend to recruit pediatric neurosurgeons due to 
the high burden spina bifida and hydrocephalus in these nations. 
There is a role for surgeons in medical education abroad through 
entities such as the American College of Surgeons.
How is the balance between family time, call-time, and day-to-
day work? 
All twelve members in our faculty are married, and most of us 
have children. I think achieving a work-life balance is very manage-
able. The Victoria Hospital neurosurgeons have a call frequency of 
1 in 4 and we do call a week at a time, but I usually go home around 
6:30 pm, and am back for meetings around 7:00 am. In general, I’m 
not up every single night operating, and we have a good vacation 
roster. Gone are the days where people are living in the hospitals 
and not seeing their families.
If a medical student is interested in neurosurgery, what advice 
would you have for them?
The best thing to do is really explore the specialty through clin-
ical electives and spend time with the neurosurgical service. That 
will give you the best perspective as to what the practice looks like 
and the pathology that you will be dealing with on a regular basis. 
It’s harder if you haven’t had that experience to look at it as a via-
ble specialty option because you really haven’t experienced what 
it’s like and you have only an abstract concept of what a neurosur-
geon might do. But that’s really advice that I give for anybody who 
is looking at any specialty. 
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An emergency room physician is asked to see a 68-year-old 
male complaining of mild chest discomfort, intermittent palpita-
tions, and worsening shortness of breath. The patient presented to 
the emergency room with an acute onset of palpitations and states 
a 3-month history of fatigue. At triage, blood pressure is 135/90 
mmHg, respiratory rate is 16 breaths per minute, and an irregular 
heart rate at 125 bpm at rest is identified. Additionally, his history is 
notable for a 30-pack-year smoking history and longstanding, rea-
sonably controlled hypertension. On further evaluation, the patient 
develops increasing confusion and light-headedness. 
A 12-lead electrocardiogram (ECG) demonstrates the absence 
of discrete P waves and an irregularly irregular ventricular rate, di-
agnostic of atrial fibrillation. However, immediately following the 
identification of atrial fibrillation on ECG, the patient begins de-
scribing a weakness in his left hand. His symptoms progress over 
the next ten minutes until he can no longer lift his arm and has trou-
ble speaking. Concerned, the emergency physician immediately be-
gins assessment of ischemic stroke. 
thrombogeneisis in atrial fibrillation
Atrial fibrillation (AF) is a supraventricular tachyarrhythmia 
characterized by uncoordinated atrial activation and subsequent 
diminution of mechanical function.1 Rapid, ectopic firing of multi-
ple atrial foci, resulting in the asynchronous depolarization of the 
atria, produces the characteristic cardiac arrhythmia. Due to the 
rapid and chaotic atrial activity, AF leads to disorganized mechan-
ical atrial function, irregular ventricular rate, and hemodynamic 
irregularities, ultimately generating a prothrombotic environment.2 
The most serious complication of atrial fibrillation is a throm-
boembolic event, such as an ischemic stroke, which can lead to 
permanent neurological damage. An ischemic stroke may occur in 
patients with AF either as the primary presenting manifestation of 
AF or in patients with previously diagnosed AF despite appropri-
ate medical management. In such patients, a cardiac embolus most 
frequently originating from the left atrium is thought to be a main 
source of ischemic strokes in patients with AF.3 
initial assessment of ischemic stroke in atrial 
fibrillation
Atrial fibrillation is the most common cardiac arrhythmia seen 
in clinical practice and is an important contributor to increased 
morbidity and mortality, largely due to thromboembolic events 
such as ischemic stroke.4,5 As a result of an acute embolic obstruc-
tion to cerebral circulation, an ischemic stroke manifests with the 
abrupt onset of focal neurologic deficits, with symptoms of stroke 
remaining indefinitely if irreversible neurological damage occurs 
as a result of the cerebral ischemia. As such, prompt assessment 
and management is key when stroke is strongly suspected. Follow-
ing the assessment of vital signs and ensuring the stabilization of 
airway, breathing, and circulation, a focused history and physical 
examination should be promptly obtained.6 
The single most influential item with regards to patient history 
in stroke evaluation is the time of symptom onset, defined as the 
last known time when the patient was at their previous baseline 
or symptom-free state.1 Determining the time of ischemic stroke 
symptom onset is of crucial importance, and acts a main determi-
nant of eligibility for acute intravenous thrombolysis treatment. For 
patients unable to provide this information at the time of presenta-
tion, consulting patient family members, bystanders, or emergency 
medical service personnel may be required. After identifying time 
of symptom onset, a thorough history and physical exam should 
follow, focusing on identifying the progression of symptoms, pos-
sible embolic sources, and any concomitant patient comorbidities 
that may impact management of an ischemic stroke. Any contrain-
dications to thrombolytic treatment should also be assessed at this 
time.6 
An initial neurological examination should be promptly per-
formed following physical examination. Formal stroke evaluations, 
as guided by documents such as the National Institutes of Health 
Stroke Scale (NIHSS), have demonstrated clinical utility as a form 
of rapid neurological assessment, and may be administered success-
fully by a broad spectrum of healthcare providers.7,8 The three most 
predictive examination findings for the diagnosis of acute stroke 
are facial paresis, abnormal speech, and arm drift/weakness.9,10 
Blood should be drawn to evaluate complete blood count, platelet 
count, blood glucose, electrolytes, cardiac markers, and coagulation 
studies. Furthermore, timely brain imaging remains critical to the 
rapid evaluation and diagnosis of patients with potential ischemic 
strokes. Imaging may be used to exclude the presence of intracra-
nial hemorrhage, assess the degree of brain injury, and identify the 
vascular lesion responsible for the ischemic deficit. Either comput-
ed tomography or magnetic resonance imaging may be used as the 
initial imaging modality for the emergent assessment of patients 
with suspected stroke.6 
The emergency physician, quickly recognizing the signs of 
stroke and noting the onset of stroke symptoms, immediately begins 
the clinical stroke evaluation using the NIHSS. Blood is drawn, im-
mediately sent to the laboratory, and imaging studies are arranged. 
An urgent consult to the stroke service is made and decisions for 
early management are considered.
When the beat clots
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acute management of ischemic stroke
Following the diagnosis of ischemic stroke, timely restoration 
of cerebral blood flow using fibrinolytic therapy is the most effec-
tive pharmacological maneuver for salvaging viable ischemic brain 
tissue.11 As previously mentioned, the single most influential item 
with regards to patient history is the time of symptom onset, in 
order to aid in determining the eligibility for acute intravenous fi-
brinolytic treatment. Additionally, any contraindications to intrave-
nous thrombolysis must also be strictly evaluated.6
For eligible patients with acute ischemic stroke, intravenous 
fibrinolytic therapy in the form of intravenous recombinant tis-
sue-type plasminogen activator (rtPA) alteplase is currently the 
widely accepted approach.12,13 Timely thrombolytic therapy admin-
istered within the therapeutic window, recognized as within 4.5 
hours from symptom onset, has demonstrated significant reduc-
tions of long-term disability with no increase in long-term mor-
tality.14,15 Most importantly, earlier treatment is more likely to re-
sult in favorable outcomes, further emphasizing the importance of 
timely emergency department evaluation and diagnosis of ischemic 
stroke.16
Intracranial hemorrhage remains the major risk of intravenous 
rtPA treatment, with early neurological symptoms associated with 
intracranial hemorrhage occurring in 6.4% of patients treated with 
intravenous rtPA.17 Thus, strong emphasis must be placed on initial 
assessment and patient history to ensure appropriate selection of 
patients for intravenous fibrinolysis. 
For patients ineligible for intravenous rtPA, a number of en-
dovascular treatment options have become available including in-
tra-arterial fibrinolysis, mechanical clot aspiration or retrieval, and 
acute angioplasty with stenting. Although these therapies may offer 
favourable outcomes, these alternative therapies should be pursued 
only in a highly selected patient population ineligible for intrave-
nous rtPA and in centres well equipped for these modalities.1 
Returning to the case, the initial investigations and imaging re-
sults return and demonstrate early signs of cerebral infarction and 
identify the site of thromboembolism. Additionally, the imaging 
results exclude any signs of intracranial hemorrhage. Without any 
contraindications to fibrinolytic therapy, and presenting within the 
narrow therapeutic window, the patient is started on intravenous 
rtPA and monitored closely for the next 24 hours.  
long-term prevention of thromboembolism in atrial 
fibrillation
Long-term management of patients with AF often involves 
three considerations: rate control, rhythm control, and prevention 
of thromboembolism. Initially, the AF management decision in-
volves the determination between either a rate or rhythm control 
strategy; however, regardless of which strategy is pursued, atten-
tion must also be directed to antithrombotic therapy for prevention 
of thromboembolism.18
Multiple clinical strategies have been proposed to stratify the 
risk of ischemic stroke in patients with AF to determine which 
patients might benefit from antithrombotic therapy. A currently 
accepted stratification scheme, the CHADS2, integrates elements 
from several strategies and identifies patients which will bene-
fit from antithrombotic therapy. The CHADS2 scoring system is 
a point-based system in which 2 points are assigned for a history 
of stroke or transient ischemic attack, and 1 point each is assigned 
for the presence of cardiac failure, hypertension, diabetes, and age 
over 75 years.19 In patients with AF and a CHADS2 score ≥1, long-
term oral anticoagulation with warfarin or a new anticoagulant, 
such as apixaban, dabigatran, or rivaroxaban, unless contraindicat-
ed, is recommended. Patients with a CHADS2 score of 0, if over 65 
years, still benefit from long-term oral anticoagulation, while pa-
tients with AF and no additional risk factors need no therapy.18 An-
tithrombotic therapy has been shown to successfully lower the risk 
of embolization in all patients with AF, however its use is associated 
with an increased risk of bleeding and requires monitoring for risk 
of bleeding complications.20,21
Due to the rapid response and recognition of the signs of isch-
emic stroke by the emergency physician, the patient suffered only 
minimal neurological sequelae. During the recovery from his isch-
emic stroke, the patient is educated on his arrhythmia and metop-
rolol is initiated to achieve rate control. Anticoagulation is also ini-
tiated to reduce the risk of further stroke—his CHADS2 score is 3. 
He is followed up by a cardiologist to review the management of his 
atrial fibrillation and risk for recurrent stroke. Further discussions 
are made to ensure proper maintenance of his hypertension and 
discuss future considerations for smoking cessation.
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introduction
In the aftermath of a traffic collision, it can be common for 
emergency responders to find the victims disoriented, confused, 
or even aggravated. Often, this is the result of the psychological or 
physical trauma sustained during the collision.1 On occasion, any 
number of prior medical conditions may be contributing to a vic-
tim’s altered mental status. These may even be the primary cause 
for their presentation, complicating the situation for both the ini-
tial responders and emergency room medical staff.2 Our case begins 
in just such a fashion. After a low-velocity collision, a 75-year-old 
Californian man was found behaving erratically and aggressively 
by emergency responders. Responders diligently removed the pa-
tient’s hat to check for injuries. Under the hat was not an injury 
related to blunt trauma sustained during the collision, as one might 
expect, but rather a lesion with exposed cerebral matter which con-
tained a clear infestation by maggots. The patient was subsequently 
brought to the emergency room for further investigation.3
While simple lesions of the scalp are often benign, resulting 
from minor trauma or common dermatological conditions, lesions 
which perforate the skin, bone, and meninges such as the one seen 
in our case are quite rare.4 Penetrating head injuries, neoplastic con-
ditions and severe cranial infections are the most likely suspects.3,5,6 
In the case of penetrating head injuries, gunshot wounds, stabbings, 
and motor vehicle collisions are the most prevalent.5 Possible neo-
plastic conditions include osteoma or osteosarcoma of the cranial 
bones, hemangioma, and angiosarcoma.3,6,7 Potential cranial infec-
tions include brain abscesses due to bacterial or fungal infections.8
case presentation & diagnosis
Investigation continued at the hospital with a patient histo-
ry provided by family members. The lesion had started as a red-
dish-purple nodule on the frontal scalp. Over the course of a year, 
it had expanded, ulcerated, and ultimately become infested with 
maggots. Although various family members had advised treatment 
for the nodule, the patient had refused, citing religious reasons. The 
patient resided with his wife, who had been diagnosed with ad-
vanced Alzheimer’s, and his contact with the rest of his family was 
infrequent. Additionally, later investigations revealed extremely 
poor living conditions, exemplified by garbage accumulation, ani-
mal fecal matter, and the presence of rodents. These factors allowed 
the lesion erosion and subsequent infestation to develop undetect-
ed until the collision.3
On physical examination, the patient displayed obvious poor 
hygiene and presented with a strong putrid odour. The patient’s 
vital signs and temperature were unremarkable. The cranial le-
sion was examined in detail. It presented with substantial erosion, 
measuring 15 cm x 17 cm, and extended bilaterally over the frontal 
cranial region from the orbital rim to the parietal scalp. Within the 
lesion the dura was absent, exposing cerebral brain tissue. Two cor-
tical defects were found around the midline of the lesion, each of 
which contained dense clusters of live maggots embedded within 
the brain tissue. A count of the number of live maggots was deemed 
impractical and not performed. The maggots engaged in active 
movement in all regions of the defect, including the surface of the 
exposed cerebral tissue.3
The patient remained conscious but torpid, and responded to 
simple commands. Further neurological examination was normal. 
A complete blood count and white blood cell differential was per-
formed, revealing a WBC count of 20 100/mm3, 91% neutrophils 
and no bands. Blood culture in the emergency room indicated the 
presence of penicillin-sensitive group G Streptococcus.3
Finally, a computerized tomography scan identified multiple 
skeletal and abdominal lesions, including a destructive soft tissue 
mass in the left posterior chest wall. This mass was centered at the 
T9 vertebral body and extended into the spinal canal. Needle biop-
sies of the lesion sites revealed poorly differentiated spindle-shaped 
CD31-, CD34-positive cells. Additionally, the patient had swollen 
parotid glands, which also tested positive for the same cell types. 
These finding supported a diagnosis of metastatic angiosarcoma.3 
management
The patient was admitted to intensive care. Broad-spectrum 
antibiotics were started, specifically a regimen of intravenous van-
comycin, ceftriaxone, and metronidazole. Maggot extraction was 
moderately successful, and was performed via gentle suction. The 
remaining maggots were covered with sterile surgical dressings 
soaked in a mild bleach solution. No living maggots remained after 
3 days.3
Psychiatric evaluation determined the patient competent to 
make his own medical decisions. The patient declined any surgery 
and any treatments for his metastatic angiosarcoma. The family as 
well as the ethics committee upheld his decision. Because he de-
clined surgery, the cortex remained exposed following treatment, 
until his death 3 months later following his transfer to a nursing 
facility.3 
discussion
Cerebral myiasis is an exceedingly rare condition, with only a 
handful of described cases worldwide. The vast majority of these 
cases have been identified postoperatively. All reported cases which 
state an outcome have unfortunately resulted in death of the pa-
tient, although the cerebral myiasis may not have been a main con-
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tributor to their deaths. In this case, the more immediate threat was 
likely the presence of group G β-hemolytic Streptococcus, which can 
present indistinguishably from a group A streptococcal infection, 
while the ultimate cause of death was presumably due to the un-
treated metastatic angiosarcoma.3,9 Indeed, without the open crani-
al lesion caused by the angiosarcoma, the maggot infestation would 
have likely been self-limiting; the short lifecycle of the fly species 
discovered (Phaenicia sericata, commonly called the green bottle 
fly) would have resulted in the elimination of live maggots within 
a week or so without continuous deposition of new eggs by adult 
flies.3,10
With the exception of the case presented here, all have oc-
curred outside North America. Reported cases of cerebral myiasis 
indicated lesions which were less extensive than the one seen in 
this case. The presence of angiosarcoma as the primary cranial le-
sion could have contributed to the extent of the infestation. Mag-
gots of the common green bottle fly preferentially feed on dead tis-
sue, and have been used in maggot therapy to debride away dead 
tissue. In this case, tumor growth may have continuously provided 
necrotic material to sustain the maggots.3,10,11
As there have been so few cases of cerebral myiasis, no stan-
dard treatment exists. Removal of the maggot infestation, as was 
conducted in this case, would seem to be an appropriate course 
of action. Broad spectrum antibiotics to treat concurrent bacterial 
infections and ward off secondary infection would also appear to 
be prudent, particularly as the presence of Phaenicia sericata lar-
vae may help protect against bacterial infections, a protection that 
may be removed with the elimination of the infesting maggots.3,11 
Evaluation of mental status should be undertaken to determine the 
extent of cognitive impairment, if any, and to establish competence 
to direct care.3
conclusion
This is an extremely unlikely case of cerebral myiasis that has 
invaded through the meninges. That this case was identified only 
after evaluation after a low-speed collision, and that cognitive func-
tion was still largely intact is truly remarkable given the extent of 
the infestation. In medicine, we are told that when we hear hoof 
beats, we should think horses, not zebras, and certainly not fiction-
al unicorns. This first reported case of cerebral myiasis in North 
America with its highly improbable presentation is about as close 
to a unicorn as we come in modern medicine.
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